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Abstract
Locating a ligand-binding site is an important first step in structure-guided drug discovery, but
current methods typically assess the pocket as a whole, doing little to suggest which regions
and interactions are the most important for binding. This thesis introduces Fragment Hotspot
Maps, a grid-based method that samples atomic propensities derived from interactions in the
Cambridge Structural Database (CSD) with simple molecular probes. These maps specifically
highlight fragment-binding sites and their corresponding pharmacophores, offering more
precision over other binding site prediction methods.
The method is validated by scoring the positions of 21 fragment and lead pairs. Fragment
atoms are found in the highest scoring parts of the map corresponding to their atom type,
with a median percentage rank of 98%. This is reduced to 72% for lead atoms, showing
that the method can differentiate between the hotspots, and the warm spots later used during
fragment elaboration.
For ligand-bound structures, they provide an intuitive visual guide within the binding site,
directing medicinal chemists where to grow the molecule and alerting them to suboptimal
interactions within the original hit. These calculations are easily accessible through a simple
to use web application, which only requires an input PDB structure or code.
High scoring specific interactions predicted by the Fragment Hotspot Maps can be used to
guide existing computer aided drug discovery methods. The Hotspots Python API has been
created to allow these work flows to be executed programmatically through a single Python
script. Two of the functions use scores from the Fragment Hotspot Maps to guide virtual
screening methods, docking and field-based ligand screening. Docking virtual screening
performance is improved by using a constraint selected from the highest scoring polar
interaction. The field-based ligand screener uses modified versions of the Fragment Hotspot
Maps directly to predict and score the binding pose. This workflow gave comparable results
to docking, and for one target, Glucocorticoid receptor (GCR), showed much better results,
highlighting its potential as an orthogonal approach.
xFragment Hotspot Maps can be used at multiple stages of the drug discovery process, and
research into these applications is ongoing. Their utility in the following areas are currently
being explored: to assess ligandability for both individual structures and across proteomes,
to aid in library design, to assess pockets throughout a molecular dynamics trajectory, to
prioritise crystallographic fragment hits and to guide hit-to-lead development.
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Chapter 1
Introduction
1.1 Drug Discovery
The discovery of new drugs is a multivariate problem. A drug is required to bind to a target
strongly and selectively, whilst having physicochemical properties that allow it to reach its
target and remain at a high enough concentration for therapeutic effect. The strength of
a compound’s binding is referred to as its affinity, with factors important for maintaining
therapeutic concentration referred to as the absorpotion, delivery, metabolism, excretion and
toxicity (ADMET) properties. Changes to a compound’s structure can lead to changes in its
activity, known as the structure-activity relationship (SAR), however ADMET properties can
also be affected by this change.
As both technologies and our understanding of disease improved, drug development
evolved and changed the way that affinity and ADMET properties were considered. Before
in vitro assays became common, use of in vivo testing meant that efficacy was being mea-
sured directly, implicitly accounting for target tractability and ADMET properties [3]. As
focus moved to testing affinity in vitro, with ADMET considered separately, it became the
responsibility of the medicinal chemist to balance these properties. The work flow shown in
figure 1.1 gives an overview of the process of a clinical candidate’s discovery.
1.1.1 Early Drug Discovery
As we entered the second half of the 20th century, drug discovery was markedly different from
today. Most notably, in vivo models were used for the primary screen [3], and projects relied
on medicinal chemists synthesising compounds in gram quantities for use by pharmacologists.
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Compound Library
Testing
Virtual Screening
ADMET Screens
Lead 
Compound 
SAR
Structural 
assessment of 
Protein-Ligand 
Interactions
Design
Synthesis
Clinical Candidate
Target Tractable?
Yes
No Terminate Project
Identify Target
Biology Validated
Yes
No Terminate Project
Fig. 1.1 Drug discovery work flow. The boxed region and red arrows show the steps taken in early
drug discovery. Orange nodes represent processes that were considered implicitly in early drug
discovery through the use of in vivo models, and lilac nodes represent optional steps. Based on a
figure from [2]
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Fig. 1.2 Structure of Piroxicam
A project’s starting point could be a serendipitous biological finding or an existing drug,
as was the case for the discovery of piroxicam [4] as a treatment for arthritis. Known
treatments included aspirin, ibuprofen and diclofenac - all carboxylic acids. They were
rapidly metabolised and excreted, and as a result required multiple daily doses. This led to
poor patient compliance and increased potential for toxicity.
Chemistry output was limited to a few compounds per week, therefore the design deci-
sions made by medicinal chemists were vital. With the carboxylic acid group identified as
the cause of metabolic liability, compounds with different acidic groups were synthesised.
The development was guided by the compound’s pKa and serum half-life in dogs. After
several chemical families were tested over five years, oxicams were synthesised, ultimately
leading to piroxicam (figure 1.2). Importantly, piroxicam was able to control the symptoms
of arthritis from a single daily dose of 20 mg. Using in vivo models throughout development
ensured that all ADMET properties were considered, however the total time from project
start to approved drug was 18 years.
From the 1980s onwards, in vitro testing became more prevalent as the biological mecha-
nisms of diseases were better understood. Ziprasidone, for the treatment of schizophrenia, is
an early example of a successful drug that benefited from supplementing in vivo research
with in vitro studies[5]. Having identified the dopamine type 2 receptor (D2) as the target
for known drugs, and that binding to the 5-hydroxytryptamine type 2 receptor (5-HT2) is
required to avoid unwanted side effects, Glennon et al. [6] searched for compounds with in
vitro binding to 5-HT2. Compound (1) in figure 1.3 was identified as a potent 5-HT2 binder.
By combining it with dopamine, the natural ligand of D2, binding to both receptors was
achieved. Further SAR and modification ultimately led to ziprasidone.
1.1.2 Modern Drug Discovery
Modern drug discovery has seen a move towards a reductionist approach, letting molecular
and cell biology play a leading role. As we are no longer dealing directly with in vivo
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Fig. 1.3 Ziprasidone
Target ID Target Validation Hit ID
Hit to Lead 
Development
Lead 
Optimisation
Clinical 
Development
Fig. 1.4 A linear overview of the modern drug discovery work flow
efficacy, the work flow (figure 1.4) requires explicit identification and validation of target.
Working with molecular targets rather than whole systems allows for much higher throughput
experiments, leading to larger initial screens. If the structure of the target or closely related
protein is available, these starting points can then be developed rationally using structure-
guided approaches. Coupled with improvements in synthetic chemistry, the SAR landscape
can be explored much more quickly, streamlining the discovery of high affinity ligands.
However, strong binding affinity alone does not yield a drug, and physicochemical properties
must also be considered.
1.1.3 Target Identification, Validation and Tractability Assessment
For a drug to be efficacious, binding to its target protein (or other macromolecule) must
result in alteration of a biological process in such a way that modifies a disease[7]. A lack of
efficacy is a major cause of failure, often arising during the very expensive clinical stages,
after large investment in the development of the clinical candidate [8]. Better identification of
disease modifying targets could therefore improve success rates and allow early termination
of unsuccessful projects [9].
There is a range of techniques for target identification, which can be grouped into two
distinct strategies: molecular and systems approaches[10]. The systems approach identifies
targets through the study of disease in whole organisms, making use of data from in vivo
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studies. Since the start of the 21st century, the molecular approach has become the primary
method for target identification. It aims to understand cellular mechanisms, and therefore
makes use of clinical samples and cell models of cells implicated in the disease[10].
Modern research generates large amounts of data. In the context of target identification,
bioinformatics can be used to prioritise disease targets [11]. Many databases have been
created to provide information on known drugs and their targets [12–16], and most recently
the Open Targets platform extends this to potential targets [17], making target identification
data available for new projects.
Once a target is identified, it can be studied further using a range of validation techniques
to suppress production of the protein as proxy for inhibition. One approach is to use antisense
technology- RNA-like oligonucleotides designed to be complementary to a region of the
target mRNA molecule[18]. Binding to the mRNA then prevents the synthesis of the target
protein. Another approach is to use gene knockouts, where animals have had the target gene
deleted or disrupted to prevent protein expression. Although powerful, animal models are
sometimes difficult to develop for certain disease types, such as psychiatric illness and stroke
[19].
Recent work by Hingorani and colleagues (preprint)[20] suggests that population genetic
association studies can be used as a "natural randomised trial." Presence of germ line genetic
variants, which cause a change in the expression or activity of a protein, is analogous
to receiving drug treatment in a randomised controlled trial (RCT) performed in phase 3.
Normally for novel targets, the phase 3 RCT is the first test within humans to see whether it
has an effect on the disease, meaning targets are not truly validated until the final stages of the
expensive drug discovery process. This approach would highlight efficacious targets at the
start of the process and greatly reduce the number of failed projects, however, it will require
datasets of genomes annotated with clinical data, raising legal, ethical and data protection
issues. Although this approach could result in better early target validation, further questions
remain regarding whether the target is suitable for treatment with a small molecule.
Drugs are usually administered in tablet form, meaning that they must be able to reach
their target starting from the gastrointestinal tract. Oral bioavailability requires drugs to be
soluble in aqueous solution, but also to be permeable through cell membranes. Lipinski et al
[21] developed the rule of 5 to show the physicochemical properties required for good oral
bioavailability.
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Poor absorption or permeation are more likely when:
• There are more than 5 H-bond donors (expressed as the sum of OHs and NHs)
• There are more than 10 H-bond acceptors (expressed as the sum of Ns and Os)
• The molecular weight is over 500
• The Log P is over 5
• Compound classes that are substrates for biological transporters are exceptions to
the rule
In 2002, Hopkins and Groom [22] recognised that some binding sites would be incom-
patible with the properties required of orally bioavailable small molecules. As a result,
only a subset of the human genome is capable of binding drug-like molecules, leading to
the concept of the "druggable genome". The intersection between the druggable genome
(~3,000) with disease-modifying genes (~3,000) give potential drug targets, estimated to be
between ~600-1500, as shown in figure 1.5. A more recent analysis by Finan and colleagues
[23] has revised the estimated size of the druggable genome to be 4,479. This increase can be
partly attributed to the inclusion of proteins targeted by biotherapeutics such as monoclonal
antibodies, which can bind to proteins that are incompatible with small molecule binding.
Usage of the word druggability has varied in the literature since its introduction, also
prompting the more recent term "ligandability" [24]. Hopkins and Groom defined a target
as druggable if it was able to bind orally bioavailable druglike molecules, but stated that
"Druggable does not equal drug target". Hajduk and colleagues’ [25] use of druggability
was simpler still, describing the target’s ability to bind a small molecule with high affinity .
Cheng et al.’s definition of druggable [26] required modulation of the target, introducing the
need to also have a functional effect. In 2011, Edfeldt and colleagues [24] recognised that
there were varying usages of the term "druggability", and introduced the term "ligandability"
to take the definition of "able to bind a small molecule with high affinity." Bauer and Breeze
[27] provide a particularly in depth description, wrapping up all target requirements of a
successful drug discovery project in the single term.
"Tractability" will be used here as an umbrella term for all of these measures, table 1.1
summarises the different tractability terms and how they are used in the literature. The
measures have been given the name used in the publication, but have also been assigned
a category that matches the definition type. The three categories used are "Ligandability",
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Fig. 1.5 Venn diagram showing the predicted number of drug targets, taken from Hopkins and Groom
[22]
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"Druglike ligandability" and "Drug Feasibility". Ligandability matches the Edfeldt definition,
druglike ligandability has the added requirement of binding a ligand with druglike properties,
and drug feasibility considers all factors a target needs to yield a drug.
Here, the drug feasibility definition of druggability will be used. Given this definition,
it is difficult to determine the druggability of a target until the advanced stages of a project,
or if a drug molecule is already known. This definition of druggability can be split into
two components: ligandability and target quality (figure 1.6a). Target quality addresses
the difficult questions such as a target’s impact on disease, and most of this assessment is
performed during the target identification and validation stage.
Figure 1.6b extends the two dimensional plot to also include ligand development. The
length of each arrow roughly represents the amount of investment put into a project. The
"Borderline Success" arrow represents a target that shows a moderate ligandability and
target quality. Ligandability assessment is available early on in a project in the form of both
experimental and computational approaches. In this example, the borderline case has met the
ligandability criteria and will be progressed, however a target with comparable target quality
and lower ligandability will be abandoned early.
Due to the complex nature of target quality, we can assume a large error along the x axis.
If a target was predicted to be a borderline success and continued on in its development, it
may become apparent late on in the project that it in fact had a much lower target quality
[23], typically during the more expensive clinical trials stages.
Protein-protein interactions (PPIs) are considered the "high hanging fruit" in drug dis-
covery [28], and projects are pursued even where ligandability is thought to be low, but the
target quality is high. Many ligandability measures attempt to predict a pocket’s ability to
bind leadlike molecules from high throughput screening (HTS), however PPIs often perform
badly in high throughput screens [29, 30]. PPIs interact across large and relatively featureless
sites [31], lacking the topologies such as large pockets, clefts and groves normally targeted
by small-molecule inhibitors. However, they do contain hotspots [32], regions of dispropor-
tionately high affinity that can act as footholds. Although PPIs are considered unligandable
by many predictive methods, they are particularly suitable for fragment-based drug design
(FBDD) [33, 24], which will be discussed further in section 1.2. Hotspots also exist within
more traditional small-molecule binding sites, showing that the ligandabilty of a pocket does
not rely on features of the pocket as a whole, but regions within the pocket. The method
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described within this thesis goes beyond providing an assessment of the pocket as a whole,
and is able to specifically identify the hotspots and the interactions that cause hotspots.
1.1.3.1 Current Tractability Assessment Methods
The most suitable method for assessing tractability for a given target will depend on the
data available. Figure 1.7 summarises the different indicators of tractability, ranging from
high confidence indicators such as the existence of an approved drug, through to the low
confidence sequenced-based prediction models. However, the most attractive targets for drug
discovery often have very little information available. Computational predictions provide the
greatest utility in this case, and compared to the other indicators, such as "existence of high
affinity drug-like molecule", have the greatest scope for improvement.
Hajduk et al.[25] were able to classify pockets as "druggable" or "undruggable" (ligand-
able or unligandable) by predicting the fragment hit rate using a regression analysis and 8
descriptors. The results of fragments screens for 23 proteins were examined, and a high
correlation between the fragment hit rate and the likelihood of discovering a nanomolar
inhibitor was found. Therefore a range of descriptors including apolar surface area, roughness
and cavity volume were used to train a method that predicted the fragment hit rate. This was
then able to classify 94% of known ligand binding sites as moderately or highly druggable.
Druggable pockets have properties that differ from undruggable ones. Schmidtke et al.
published a freely available druggability dataset[34]. It used Cheng et al.’s definition of
druggable (1.1), and a druggable cavity directory was created by cross referencing lists of
oral drugs with the protein data bank (PDB) [35]. Analysis of this dataset showed druggable
binding sites contain 20-40% polar surface compared to 40-60% for non-druggable sites. 70%
of the polar atoms in druggable sites are found to have small solvent exposed areas, which
decreases to 50% in undruggable sites. In druggable sites the polar atoms are surrounded by
a hydrophobic region, and are found to protrude into the cavity, making them more available
for interaction.
Datasets of druggable proteins have been used to create computational druggability pre-
diction methods. Cheng’s dataset was used for SiteMap[36], whereas a more recent program,
DogSiteScorer[37], extended the Cheng dataset with Schmidtke’s[34] and Hajduk’s[25]
datasets. In all of these cases, machine learning was used in conjunction with multiple
descriptors to differentiate between druggable and undruggable pockets. A disadvantage
of this approach is that the pocket is considered as a whole, and loses fine details such as
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(a) Druggability split into its two components of target quality and ligandability. The green area
represents a druggable target
(b) Including ligand development, an arbitrary measure of time and money, on the z axis. Each
arrow represents a drug discovery project, with the start of arrow representing the target quality
and ligandability (i.e. the druggability) and the head representing the outcome. The green region
represents a successful project
Fig. 1.6 Relationship between target quality, ligandability and druggability
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Fig. 1.7 Overview of protein tractability assessment
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the location of the hotspot. This means that such a method is unsuitable for the finer detail
prediction of fragment binding sites.
1.1.4 Hit Identification
1.1.4.1 Computational
In modern drug discovery, most projects are backed up by computational support. computer-
aided drug design (CADD) has two main branches: molecular modelling and chemoinfor-
matics, both of which are able to able to assist in hit identification.
Molecular modelling is a broad term covering techniques that predict molecular behaviour,
structure and properties. In the context of hit identification this means using known proteins,
protein-ligand complexes and/or small molecules to suggest which compounds are likely to
bind to the target, a process referred to as virtual screening. Virtual screening techniques filter
or rank large virtual libraries to prioritise which compounds should be tested experimentally.
Although virtual screening faces challenges, explored in detail in chapter 5, it can to provide
an enrichment of active molecules in a subset of a larger library.
Chemoinformatics is the use of informatics to solve chemical problems[38]. The methods
used are typically fast, and applicable to databases of molecules. Molecules can be repre-
sented in numerous ways. Fingerprints, or binary string representations, are a highly efficient
description molecule. A series of 1s and 0s represent the presence or absence of a certain
chemical feature, and these fingerprints can be rapidly compared to show their similarity.
The application of this method to virtual screening will be discussed further in chapter 5.
Simplified molecular line input entry system (SMILES) notation[39] and InChI[40] provide
two linear notations that can be used to generate the 2D structure of compounds. The CAN-
GEN algorithm[41] can be used to create canonical SMILES representations for compounds,
useful for assessing whether there is an exact match between two molecules.
In addition to finding similar molecules to known actives, chemoinformatics can aid hit
identification by identifying a representative subset of library. Clustering groups together
similar compounds, and picks one as a representative of that cluster. If a chemical database
contains 1,000,000 molecules, but screening capacity is limited to 100,000, clustering can
provide the most diverse subset of the database, providing the greatest coverage of chemical
space.
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1.1.4.2 High Throughput Screening
During the 1990s, combinatorial chemistry and parallel synthesis led to large libraries of
compounds [42–44], and automation of assays with fluid handling robots[45] provided a
means to test them - HTS. The Human Genome Project’s mission to squence the human
genome was underway[46], and by the mid 90s was able to identify genes involved in
disease. With so many targets and compounds to screen, the screening technology was seen
as partially limiting[47]. HTS attracted a lot of investment, as pharmaceutical companies
set to capitalise on this opportunity. Organisations using HTS previously able to screen 20
targets per year with a library of around 75,000 compounds could screen 100 targets with
one million compounds by the late 90s.
While previous methods aimed to make use of existing knowledge to discover hits, HTS
takes an intellectually neutral approach. Emphasising large libraries and fast experiments,
HTS relies on active molecules being present amongst the hundreds of thousands in the
screen. Initially it was hoped that it would be possible to derive drugs directly from an HTS
screen[48], however even with multi million compound screening decks, the output is limited
to chemical starting points in need of optimisation. This limitation can be explained by the
size of leadlike [49] chemical space, which represents all potential molecules with leadlike
properties. It is estimated that there are more than 1×1030 possible molecules[50] and even
the largest HTS screening deck represents a tiny fraction of this space.
Early libraries were put together based on the previous activities of the company, with
little consideration of the suitability of the compounds. Furthermore, early combinatorial
chemistry relied on a small number of reactions, leading to limited diversity. As the success
of HTS relies on how well leadlike chemical space is covered, companies made large
investments to improve this coverage. First, collections were cleaned up by removing
compounds with undesirable properties, with some libraries having as much as 40-50% of
compounds removed[51]. Following this, there were large investments to increase library
size with carefully selected compounds. Chemoinformatics was used to ensure diverse
chemotypes were selected, whilst also considering leadlike properties. Although these later
HTS libraries still showed poor coverage of lead-like chemical space, this optimisation
resulted in a better representation of this space. A more recent approach with a far greater
coverage of chemical space, called FBDD, will be discussed later in section 1.2.
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1.1.4.3 Focused Screening
An alternative to trying to maximise coverage of chemical space is to focus on a relevant
region of chemical space. Libraries can be designed to interact with either an individual target
or a family of related targets. Libraries can be created by using known actives of similar
binding sites[52], or rationally designed using in silico methods[53]. Simply recycling known
actives is likely to run into intellectual property (IP) problems, therefore it is important to
combine information about known ligands with structure-based methods to modify side
groups around key cores. This approach is less likely to identify novel starting points for a
drug discovery project, but offers a more efficient approach compared to HTS.
1.1.5 Hit-to-Lead Development
1.1.5.1 Structure-Guided
By the mid 1980s, drug discovery projects began to make use of protein structures to
rationally design molecules. In cases where the target’s structure was unavailable, models
could be created based on homologues for which a structure was available. An example of
this was the use of endothiapepsin’s structure (figure 1.8b) with the program FRODO [54] to
create a model for renin[55] (figure 1.8a), a target of interest in the search for a new treatment
for hypertension. The similar 3D shape of these models could be used by medicinal chemists
to grow their molecules whilst maintaining shape complementarity between the protein and
the ligand.
The manual process of creating a model from a related structure was initially viewed
with scepticism from the protein crystallography community [56], therefore Blundell and
colleagues set out to automate this process to make it more widely accessible. The first
program, COMPOSER [57, 58], assembled fragments of structures from homologous pro-
teins. A later program, MODELLER [59], used spatial restraints based on knowledge from a
related protein, and became widely used in both academia and industry.
In time, it became more common to have a protein structure available for your target
of interest. The scope of a structure’s utility in a project extended beyond simply guiding
the growth of known binders, with application much earlier on. Protein structures were
used to assess the tractability of a target, providing information such as whether the target
has a suitably sized pocket available for binding. In addition to visual inspection of protein
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(a) Renin (b) Endothiapepsin
Fig. 1.8 Cartoon representation of two aspartyl proteases
structures, computational methods were being developed to interrogate this information rich
resource.
GRID was developed in 1985 by Peter Goodford to computationally map protein binding
sites with favourable regions for a given probe. As the name suggests, this method produces
a grid output, which can be used visualised as 3D contours over the protein structure, guiding
medicinal chemists.
Improvements in computational power and methods allowed structure-based approaches
to be used in hit identification. The most common structure-based computational approach
is molecular docking. DOCK was developed in 1982 [60], initially used for binding mode
prediction, vitally important for structure-based drug design. Ten years later, Kuntz described
how DOCK can be used to computationally assess hundreds of thousands of compounds,
now referred to as virtual screening.
1.1.5.2 Trends
One of the key aims during hit-to-lead development is to improve affinity for the target,
however this needs to be balanced against physicochemical properties that may lead to
ADMET issues. In the late 2000s, it was widely recognised that a decrease in drug discovery
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productivity was partly due to poor quality compounds entering clinical trials [61, 62], with
Leeson et al blaming the increased lipophilicity of compounds leading to promiscuity [61]. In
2011 Walters and co-workers [63] showed that between 1959 and 2009, molecular properties
of lead compounds were diverging from those of known drugs, becoming larger, flatter and
more lipophilic.
Keseru and Makara looked at the properties of hits and their subsequent leads from
various screening methods [62]. They found that hits from HTS had worse properties than
those discovered from fragment-based screening (discussed below) or natural products.
Despite this, the properties of subsequent leads were the same, regardless of the screening
method, demonstrating a tendency to gain potency through hydrophobic interactions during
hit-to-lead. This demonstrates a need for careful optimisation of multiple parameters rather
than affinity alone.
1.2 Fragment-Based Drug Discovery
Fragments are molecules that typically have a molecular weight between 120 and 250 and
8-18 heavy atoms. They follow a rule of 3 [64], analogous to Lipinski’s rule of 5 [21].
Compared to high throughput screening, fragment-based drug design has an emphasis on
efficiency, screening fewer compounds and synthesising fewer compounds in hit-to-lead.
FBDD tends to ultimately result in compounds with more desirable properties[65].
Fragments are particularly good at exploring binding sites due to their low complexity[66].
As the size (and therefore complexity) of the molecule increases, the likelihood that it will
complement the binding site decreases, however when complementarity is achieved the
binding affinity is higher. Therefore more simple molecules will complement the binding
site more often, but at an affinity often too low to be detected by traditional assay techniques.
This suggests an optimal size for maximising useful binding events, where you have comple-
mentarity between the protein and the ligand at a detectable affinity. This demonstrates the
importance of designing a suitable fragment library to match the sensitivity of your chosen
screening technique.
∆GBinding has been shown to be related to the number of heavy atoms[67], and as
fragments typically have fewer than 15 heavy atoms, they have a limited potential for binding
compared to larger drug like molecules. Hotspots are sites able to interact efficiently enough
with fragment molecules to overcome the limited number of interactions[68], and once the
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fragments are developed further into drug-like molecules, the moiety corresponding to the
original fragment is very sensitive to modification.
Ligand efficiency[22] provides a means to compare the affinity of different sized molecules.
Aiming to improve ligand efficiency rather than affinity discourages gaining potency rel-
atively easily by adding large lipophilic groups. Ligand efficiency is defined in equation
1.1.
LE =
∆G
Numbero fHeavyAtoms
(1.1)
This idea was developed further by the introduction of Group Efficiency[69], shown in
equation 1.2. Group efficiency helps medicinal chemists to decide whether the addition of
a group gives a sufficiently large increase in affinity, providing a guideline to suggest how
much potency should be gained as a function of the number of heavy atoms added.
GE =
∆∆G
∆Numbero fHeavyAtoms
(1.2)
1.2.1 Screening Methods
Fragment screening typically starts with a cascade of assays[70–72, 68], starting with high
throughput methods such thermal shift assay (TSA) [73–75] or surface plasmon resonance
(SPR) [76, 77], with hits followed up by isothermal titration calorimetry (ITC), nuclear
magnetic resonance (NMR) spectroscopy[78] and X-ray crystallography[79, 80]. ITC gives
high quality information about the free energy, entropy and enthalpy of binding. NMR can
show which residues interact with the ligand, and the X-ray crystal structure that can show
the exact binding mode of the fragment.
It is also possible to bypass filtering with thermal shift or SPR, and use X-ray crystal-
lography as an initial screen [81, 79]. Nienaber and colleagues [82] created cocktails of up
to 100 fragments, which can be differentiated by their electron density, to allow screening
of thousands of molecules per day. A disadvantage of such a large number of fragments
within a cocktail is the low concentration of each individual fragment, important for the
detection of weakly bound, but useful hits. Improvements in library design, cocktail design
and soaking methodologies led to changes in screening methods [83]. Astex pharmaceuticals
employs this approach [84], using cocktails of five diverse fragments that can be not only
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easily differentiated by their electron density, but also reduce the likelihood of multiple
fragments binding.
Schiebel and colleagues [85] compared six different screening methods to X-ray crystal-
lography, looking at endothiapepsin. Previous attempts [86, 87] to screen with a fluorescence-
based high concentration biochemical screen (HCS), saturation-transfer difference NMR
(STD-NMR), reporter-displacement assay (RDA), native mass spectrometry (MS), microscale
thermophoresis (MST) and TSA had shown very little overlap. While two thirds of the library
were detected as potentially binding, only 41 out of 361 fragments were identified by two or
more methods, and no hit was found in all six assays. Due to poor overlap, crystallographic
screens were performed using single compound soaks of all 361 fragments. The authors were
able to find 71 hits (20% hit rate), 31 of which had not been found by any of the biophysical
assays, and a further 21 were only predicted by one assay. In this example, the use of a
cascade with two or more screening techniques would have failed to identify 73% of the
crystallographic hits.
The authors note that the fragments found by biophysical assays only bound close to
the catalytic dyad, whereas fragments identified by crystallography alone found 11 binding
sites in total [88]. They continue to say that the binding sites from fragments identified
in the biophysical assays present the best starting point for fragment growth, whereas the
additional sites found in the crystallographic screen provide important structural information
that can be used for fragment growing. An overlay of all 71 fragments is shown in figure 1.9.
Neighbouring proteins in the crystallographic environment have been included to highlight
the fact that some of the extra fragment-binding sites can be an artefact of crystal contacts.
The hotspot predicted by the method described within this thesis, Fragment Hotspot Maps
[1], has also been displayed. The predicted hotspot coincides with the fragments highlighted
by the authors as the best starting points for fragment growth.
Recent work by Frank von Delft and colleagues represents the cutting edge of high
throughput crystallography. Their highly automated XChem facility can screen up to 1000
compounds individually within a week [89]. A recently developed method, PanDDA [90],
utilises the large amount of data produced by XChem to provide a much clearer view of ligand
electron density. Their method uses the electron density from the many apo structures, which
are generated in cases where fragments do not bind, as a way to remove noise. As a result,
they are able to locate many more fragment binding sites, even when they are only partially
occupied. While this work represents an important step forward in protein crystallography,
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Fig. 1.9 Endothiapepsin displayed with 71 fragments. Fragment Hotspot Maps [1], introduced in
chapter 2, are displayed as yellow (apolar), red (hydrogen bond acceptor) and blue (hydrogen bond
donor) surfaces. Ligands are displayed as white sticks, endothiapepsin is displayed as a green surface
and neighbouring proteins in the crystallographic environment are displayed as a white surface
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it also presents a challenge. Much like the endothiapepsin example above, not all of these
fragments will be suitable starting points for development, but offer important insight that
can guide the hit-to-lead development. The Fragment Hotspot Map method, described within
this thesis, may provide a computational approach to help categories fragments as those
that will make good starting points, and those that can be used as information to guide the
subsequent fragment development.
1.2.2 Fragment Development Strategies
Once a fragment hit is identified, it needs to be developed further to gain sufficient affinity.
Despite starting from millimolar potencies, it is possible to obtain a nanomolar lead compound
through the synthesis of 20-100 molecules from the the starting fragment hit [91]. This is
made easier if knowledge of key interactions is available from X-crystallography or NMR,
although a recent poll on the practical fragments blog http://practicalfragments.blogspot.co.uk
showed that just under half of respondents (143 total) would begin fragment development
without structural information (figure 1.10). Although it is possible to develop fragments
without a structure [92], I will focus on structure-guided methods as they offer the best
opportunity to develop efficient leads, and are the most relevant to this thesis.
There are three main strategies available for the development for fragments; linking,
merging and growing. Fragment linking was introduced as the first fragment based approach
in SAR by NMR by Shuker and colleagues [78]. Two fragments with micromolar affinities
were tethered together to create a nanomolar inhibitor. Fragment linking was supported by
computational approaches such as CAVEAT [93], HOOK [94] and CONCERTS [95], which
aimed to link two proximal molecules in the binding sites. A requirement for successful
fragment linking is the design of an optimal linker that is capable of maintaining the binding
positions of the two fragments. Despite the support of computational approaches, this has
proven difficult in practise, and fragments are susceptible to movement during the linking
process [96].
Fragment merging potentially faces the same pitfalls as linking. However, if two frag-
ments show suitable overlap with a common group or ring, they may be combined to form a
single molecule. This has been demonstrated by Nikiforov and co-workers [97] in the search
of inhibitors of the Mycobacterium Tuberculosis target EthR. Two micromolar fragments
showed partial overlap, and when combined led to improved affinity and retained the binding
position of the two parent fragments.
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Fig. 1.10 Break down of 143 responses to the question: "how much structural information do you
need to begin optimising a fragment?” From the practical fragments blog written by Dan Earlanson
http://practicalfragments.blogspot.co.uk/2017/06/poll-results-what-structural.html
Fragment growing is a more straightforward approach, as it only requires a single starting
point. The orientation of the fragment in the binding site is used to grow the fragment and
pick out additional interactions. This can be aided by docking, or simply through knowledge
of the binding site [98]. Once again, it is important that the original binding position is
maintained in the fragment upon elaboration. One might expect that as other interactions are
introduced, the original fragment portion of the lead compound could be pulled away from
its original position. This is not the case, and it is typical for the initial fragment to show
very little movement during elaboration [99]. Fragments are suitable for elaboration if they
are anchored in place at a binding hotspot. As this is not necessarily clear from the structure
alone, computational methods can help to prioritise which fragment to take forward.
1.3 Hotspots
Many proteins have pockets that have evolved to bind small molecules, and within these
pockets are hotspots; areas that make a disproportionately large contribution to binding
affinity [32]. The idea of small molecule hotspots evolved hand in hand with fragment-based
drug design (FBDD). In 1996, Karen Allen [100] and colleagues described their multiple
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solvent crystal structure (MSCS) method, solving the structure of porcine pancreatic elastase
with acetonitrile as the probe organic solvent. The authors noted that their work had a
"theoretical counterpart," the multiple copy simultaneous search (MCSS) method described
by Miranker and Karplus in 1991 [101]. However, while the computational MCSS found a
large number of favourable binding positions, the experimental MSCS found that the probe
molecules only bound to relatively few sites.
In the same year, Rejto et al [102] found that the pipecolinyl moiety of FK506 acted as
a "molecular anchor" for binding to FK506 binding protein (FKBP-12). Recognising the
importance of the location at which the pipecolinyl moiety bound, they addressed this by
splitting FK506 into fragments. Each of these was docked into the binding site, and all seven
of them bound to the hotspot, rather than rediscovering their original binding poses. Months
later, Shuker and colleagues [78] published their work on "SAR by NMR". Compounds with
nanomolar affinities were discovered by linking together two smaller fragments that were
found to bind to proximal sites.
In 1999, the MSCS method was studied further in two separate papers [103, 104], both of
which finding once again that there were far fewer binding sites than computational methods
suggest, which do not take into account solvation and entropic effects. Two years later,
another MSCS paper from English and co-workers [105] compared their experimental results
with GRID [106] and MCSS. Once again, they found that only a handful of the predicted
sites corresponded to experimental sites, this time making the connection to previous work
by Clackson and Wells [107] describing hotspots at protein-protein interfaces. In their
discussion, the authors make an important statement:
...a disparity in the predictions might be anticipated since entropic and solvation effects
were not explicitly included in the calculations. In general, electrostatic interactions
dominate the computational predictions as they tend to be overestimated in vacuo.
This comparison serves to highlight the amphipathic nature of these probe molecules
(particularly isopropanol and acetone), with the observed binding mode representing a
compromise between hydrophobic and hydrogen bonding interactions.
This observation turned out to be a fundamental one. The computational method described
within this thesis was designed with this observation in mind, and other successful hotspot
detection methods can be attributed to the direct or indirect handling of this idea, which will
be discussed further in chapter 2.
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Ligandability
Hotspots
Fragments
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correlates with 
ligandability
Fragments bind to 
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Fig. 1.11 Relationship between hotspots, fragments and ligandability. The red boxes show established
ideas from the literature.
A second observation was that the identified probes could be used to generate pharma-
cophores for database searching, or to design more focused libraries for screening a given
target. The latter idea provided a crystallographic alternative to the SAR by NMR approach,
[78, 108], a precursor to crystallographic fragment screening [84].
Fragments, hotspots and ligandability are fundamentally linked, and it is this relationship
that makes hotspot detection methods useful (figure 1.11). In 2005, Hajduk and colleagues
[25] demonstrated a strong correlation between fragment hit rate and the ability to develop a
high affinity inhibitor. Years later a similar analysis was performed within AstraZeneca [24],
which took into account fragment hit rate, affinity and diversity of hits to score 36 projects
from 2001-2008. All projects classified as "low ligandability" failed to yield HTS hits that
entered hit-to-lead, although two of these found success with fragment-based approaches.
Multiple fragments typically bind to the same region of the binding site - the hotspot.
In order for detectable fragment binding to occur, it must overcome two things: a limited
binding interface [67], and loss of rigid body entropy [109]. Although the loss of rigid
body entropy affects all ligands, the size of the penalty is mostly independent of size, and
estimated at 15-20 kJmol−1. Equation 1.3 shows the free energy of binding broken down
into ∆Grigid , the free energy associated with the loss of rigid body entropy upon binding,
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and ∆Gintrinsic, the remaining free energy terms that contribute to binding. Hotspots are
capable of contributing enough to ∆Gintrinsic in a concentrated area to bind fragments [68].
Computational hotspot prediction methods have been used to predict both fragment binding
sites and ligandability [110].
∆Gtotal = ∆Gintrinsic+∆Grigid (1.3)
1.4 The Cambridge Structural Database
1.4.1 What is the CSD?
The Cambridge Structural Database (CSD) was founded in 1965 by Olga Kennard as a
worldwide repository of small molecule crystal structures. The database is maintained by
the Cambridge Crystallographic Data Centre (CCDC), who are responsible for curating
new structures and providing access to the data. The CSD provides two key benefits to
the scientific community. Firstly, it provides a single collection of standardised structures,
allowing for easy sharing of high quality data. Secondly, the CSD can be studied as a whole.
In 1997, Olga Kennard recalled her thoughts at the inception of the CSD [111]:
The database was established in 1965 to fulfil a dream of myself and a great scientist,
the polymath J.D. Bernal. We had a passionate belief that the collective use of data
would lead to the discovery of new knowledge which transcends the results of individual
experiments.
Both the number of structures within the CSD and the rate at which they are added are
increasing each year, as shown in figure 1.12. Small molecule crystallography can achieve
higher resolution than in proteins, and hydrogens are now routinely visible in the electron
density. With the correct tools to access the data, the structural data in the CSD has become
an invaluable resource.
1.4.2 Using Small Molecule Structural Data in a Drug Discovery Con-
text
The vast amount of data in the CSD allows researchers to answer fundamental questions
about molecular geometry and interactions. Access to molecular geometry data in the CSD
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Fig. 1.12 Number of entries in the CSD by year. The red portion of the bar represents the number of
new entries added that year
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Fig. 1.13 Using mogul to aid the design of inosine monophosphate dehydrogenase (IMPDH) inhibitors.
(Left) Strained IMPDH inhibitor. (Middle) Three structures with the key torsion angle highlighted.
All three compounds have the same torsion angle once bound to the protein, but yield different
affinities. (Right) Torsion angle distributions from the CSD. The vertical line represents the torsion
angle required for for binding, and the histograms show the distribution of torsion angles for the given
environment. Figure taken from original publication [113].
was greatly improved in 2004 with the introduction of Mogul [112]. This provided a simple
interface for querying the CSD for bond-length, valence-angle, and torsion-angle distributions
and statistics. This information can be used to optimise the conformational preference of
a ligand such that it experiences minimal strain upon binding. This is exemplified [113]
in figure 1.13, where three inosine monophosphate dehydrogenase (IMPDH) inhibitors of
varying activity are shown. The slight changes to the compounds do not change the number or
quality of interactions, and all three adopt the same pose, with a key torsion angle remaining
at 110◦. The difference is highlighted by the mogul distributions on the right hand side of
figure 1.13, the required torsion angle is shown as a vertical line and in the original compound
this is rarely observed in the CSD. Introduction of an allylic bond changes the preferred
torsion from 180◦ to 120◦, improving IC50 from 1 µM to 0.14 µM. Finally adding a methyl
to one end of this bond moves the preferred torsion even closer to the 110◦, and IC50 is
improved further from 0.14 µM to 0.02 µM.
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Fig. 1.14 Creation of SuperStar maps from IsoStar data. (Left) 2D diagram of dimethyl sulfoxide
(DMSO) the central group, and NH nitrogen donor probe. (Middle) scatter plot of NH probes around
the aligned DMSO central group. (Right) Blue surface showing isocontour of donor propensity,
adapted from Wood et al. [116].
In addition to molecular geometry, and central to the work described in this thesis is the
description of molecular interactions. Interactions in the CSD encompass all of the short
range interactions between ligand and protein functional groups. There are two key pieces
of software to explore interaction data in the CSD. The first is IsoStar [114], a library of
molecular interactions that can be used to display the 3D distribution between a central group
and contact group. All of the interactions between the central and contact groups are overlaid
onto the central group, creating a "scatterplot" of contact group positions. This information
is useful for assessing the interactions around a single functional group, however multiple
functional groups can affect the same region of space, particularly in concave protein binding
sites.
SuperStar was created in 1999 [115] to provide a clear way to map whole protein binding
sites. It uses the data from IsoStar to create maps of propensity for a probe on a grid,
a knowledge-based equivalent of GRID [106]. SuperStar breaks the input protein into
fragments that correspond to IsoStar central groups. The chosen SuperStar probe, which will
correspond to an IsoStar contact group, will be used to create an IsoStar scatterplot around
the central group. These scatterplots are aligned to their original position in the protein, and
each individual scatterplot is converted to a density map. These density maps are normalised
and combined to provide a single description of the entire protein binding site. An overview
of the process is shown in figure 1.14
A key feature of using a knowledge-based approach to describe interactions is that
interaction types do not need to be defined, only probe types. If an interaction between a
probe and central group is favourable, or more importantly competitive in comparison to
other interactions [117], it will result in a signal. This is valuable as obscure but important
interactions have the potential to be overlooked [118].
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1.5 Aims
In this thesis I will describe a computational method for the identification of hotspots starting
from just a protein structure. The Fragment Hotspot Maps method will provide a means of
identifying fragment binding sites, providing information not only about where fragments
will bind, but also which interactions are the most important. In order to best represent
prospective use, the method will be run globally on apo protein structures. Once the method’s
ability to highlight fragment binding sites has been demonstrated, attention will turn to its
utility in structure-based drug design.
Chapter two will first explore the literature that highlights the physical nature of hotspots,
and gives a definition of a hotspot within the context of this project. The steps taken during
a Fragment Hotspot Maps calculation will be described and justified in terms of these
conclusions.
Chapter three will describe the method’s validation, which considers hotspots as defined in
chapter two. In addition to assessing the method’s performance across the whole dataset, two
examples with published group efficiency (GE) analysis are explored in detail. Finally, this
chapter will look at how Fragment Hotspot Maps can be used directly to aid structure-based
drug design, without any further analysis.
Chapter four will describe work that aims to improve the access to Fragment Hotspot
Map calculations. An intuitive web server has been set up for people unaccustomed to
running command-line tools, providing a means both to set up protein for the calculation and
to visualise the results. In order to facilitate using the results for those more familiar with
scientific programming, a Python-based Hotspot API has also been developed. This provides
the ability to automate calculations over large numbers of structures, with functions to help
use the results in wider work-flows.
Chapter five will demonstrate the ability of the Fragment Hotspot Maps to guide structure-
based virtual screening. This used the Hotspot API described in the previous chapter, and
two virtual screening methods, each run with and without the information from the Fragment
Hotspot Maps.
Finally, chapter six will take a look at how Fragment Hotspot Maps are being used
currently by collaborators. It will outline future plans and recent enhancements that have
been made to further increase the Fragment Hotspot Maps’ domain of utility.

Chapter 2
Development and Theoretical Basis of
the Fragment Hotspot Maps Method
2.1 Introduction
This chapter will describe the early work that ultimately formed the rationale behind the
Fragment Hotspot Maps method. The first task was to explore the existing hotspot detection
methods, comparing how they defined hotspots and what could be learnt about their nature.
This information was used to guide how Fragment Hotspot Maps were calculated and
validated.
Atomic interaction methods SuperStar [115] and GRID [106] are two well established
programs that are able to locate favourable positions for atomic probes on a protein surface,
however they would not necessarily result in an environment suitable for ligand binding.
GRID places an atomic probe at each point on a 3D grid placed over a protein, and calculates
favourable positions for a given probe using force fields. SuperStar uses data from IsoStar
[114], a library of molecular contacts in the Cambridge Structural Database (CSD) [119, 120],
to give a propensity for a given probe type at each grid point within the cavity. If an interaction
between two groups at a certain distance and angle is favourable, it will occur more frequently
in the CSD and therefore have a greater propensity in the SuperStar output. These methods
are useful, but tend to find too many favourable regions, as calculations do not include solvent,
which would normally interact with polar residues.
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Consensus site methods Sub-pockets that are found to bind a variety of chemically diverse
probe molecules can be referred to as consensus sites. The number of different probes that
bind to the site is considered rather than the binding affinity of the probe. Consensus
sites can be identified experimentally through Multiple Solvent Crystal Structures (MSCS)
[100, 121, 105] and fragment library screening [25], or predicted computationally using
simulated annealing of chemical potential (SACP)[122] or FTMap [123–125].
FTMap uses 16 small molecule probes, which are either purely hydrophobic or contain
one or two polar functional groups. FTMap ranks its hotspots by counting the number of
different types of probe that bind to a given cluster, resulting in a consensus site, reflecting
results from experimental multiple solvent crystal structures. Although consensus sites are
ranked by their promiscuity, the simplicity of the probes allows many of them to find a single
hotspot, making the single polar interaction (if required) and place their carbon atoms in the
hydrophobic region surrounding it.
Unhappy water site methods The role of binding site waters is becoming increasingly
prominent in structure-based drug discovery [126–132]. Molecular dynamics methods such
as WaterMap [130] calculate the thermodynamic properties of hydration sites, identifying
“unhappy water” sites. Water-centric methods have been included as a hotspot detection
method as unhappy waters are found within hotspots [132]. Using molecular dynamics in
explicit water leads to calculation times of approximately 24 hours, but identification of
hydration sites leads to finer grain information about the interactions likely to be the cause of
the hotspot.
Mixed solvent molecular dynamics A recent review on mixed solvent molecular dynam-
ics (MD) by Ghanakota and Carlson [133] discusses the wide range of methods available
[134–142]. The earliest was from Seco, Luque and Barril, who later developed MDMix.
MDMix[143] uses three 20 ns MD simulations, with one in the presence of 20% ethanol
and another in 20% acetamide. These probes are chosen as they are highly miscible in
water, removing the need for artificial potentials to prevent aggregation, as well as containing
the three common interaction types: hydrogen bond donor, hydrogen bond acceptor and
hydrophobic. They compare their results to GRID[106]. Without explicit solvation, they find
that GRID locates too many polar interaction sites, which correspond to favourable water
binding locations. In contrast, MDMix’s solvent probes are more selective in displacing
water molecules that are displaced by ligands.
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2.1.1 Limitations of Current Methods
Hotspot detection methods add the most value when little is known about the target. Of the
methods described above, FTMap and SACP are the only methods able to detect hotspots
from a global search of an apo protein structure, whereas the rest are validated against
predefined binding sites. These methods instead aim to map the interactions, or hydration
sites in the case of WaterMap, within a binding site to show which are likely to be made by
the ligand. None of the methods described above aim to do both.
As with all structure-based computational methods, protein flexibility should be consid-
ered. Kozakov and colleagues [144] have shown previously that hotspots are less sensitive to
conformational change. Looking specifically at protein–protein interaction hotspots, they
found that even if substantial conformational change was required for ligand binding, the
hotspots were still detectable from the apo structure.
Large changes will affect the mapping of interactions within the binding site. A well
known example of such a change is the DFG-in to DFG-out conformation change required
for type II inhibition of kinases [145]. This is exemplified in figure 2.1, where a type II p38α
inhibitor is overlaid with the apo binding site. The morpholine occupies the DFG-out pocket,
which is not present in the apo structure, and any method that uses the apo structure would
fail to predict these interactions. However, this is not solely a problem for static methods. MD
hotspot prediction approaches have insufficient sampling for such a conformational change
to occur [146], and they often require restraints on the protein heavy atoms, preventing even
small changes from occurring. Furthermore, not all ligand binding pockets exist in the protein
crystal structure until they are ligand bound. Prediction of these cryptic pockets is especially
difficult, and requires enhanced sampling MD methods [147–151]. Static methods with fast
enough calculation times could be used to post process frames from these MD calculations,
however FTMap requires 4-24 hours for a calculation [110].
2.1.2 Choosing a Hotspot Definition
Due to the broad usage of the term hotspot in drug discovery, it is important to first give a
precise definition in the context of this thesis. The chosen definition will decide how the
method is validated, therefore it is important to select one that can be compared to reliable
experimental data.
Early work during this project explored the idea that hotspots contribute a disproportion-
ately large amount to the free energy of binding (∆Gbinding). FBDD projects that had affinity
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Fig. 2.1 A type II p38α inhibitor (cyan sticks) overlaid with the apo binding site (white surface)
data available for the fragment, lead and intermediate steps, in addition to a crystal structure
for the lead molecule, were used to create 3D matched molecular pairs (MMPs). An MMP is
a pair of molecules with a single transformation between them [152]. This could be a single
cut in the case of a terminal group, or a double cut in the case of a core replacement. These
were identified using the algorithm implemented by Hussain and colleagues [153] within
RDKit.
MMPs are typically used in lead optimisation, aiming to improve target independent
properties such as solubility [152]. They are usually not used to predict affinity as this is
receptor specific. Addition of a group may have a positive effect for one target, but a negative
effect for another. In order to use MMPs to understand activity profiles, they must first be
placed in the context of the receptor [154, 155], in this case using the crystal structure of
ligand bound protein.
The MMPs between the compounds were filtered such that only additions were included.
As a result, the change in ∆Gbinding between a MMP (∆∆Gs) represents the interactions of
the group and are not affected by the loss of another group. The ∆∆Gs were then divided by
the number of heavy atoms to give the group efficiency (GE equation 1.2), which could then
be mapped to the centroid of the group using the coordinates from the crystal structure. This
2.1 Introduction 35
Fig. 2.2 3D Matched Molecular Paris (MMPs) for Protein Kinase B. (Top) 2D structures of compounds
used to generate the 3D MMPs, modified from [69]. (Bottom) 3D MMPs are represented by spheres,
which are placed at the centroid of the initial pyrazole fragment and each subsequent addition. Darker
red denotes a more group efficient moiety and the size of the sphere is related to the number of atoms
contributing to the group.
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was done for all of the identified MMPs, and displayed as a coloured sphere placed at the
centroid for each group.
An example output is shown in figure 2.2, which uses GE data for protein kinase B (PKB)
from the publication introducing GE [69]. One important caveat to the data given in this
paper is that the loss of rigid body entropy [99] has been accounted for in the calculation of
GE for the initial fragment hit.
Other datasets were gathered from both the literature, and systematically from ChEMBL
[156]. It soon became apparent that creating a dataset of known hotspots using this approach
would be difficult. The method is highly dependent on the amount and quality of data, with
few examples of projects able to clearly map the binding site. A requirement of the method
was that only additions were made to the molecule, and it was rare to find cases where there
was such a linear development for the lead molecule. As a result, the original fragment hit
was often not a valid substructure of the lead molecule, leading to the situation in figure 2.3
where the smallest valid molecule made up most of the final structure. The identification of
the hotspot through this method relied on inclusion of the rigid body entropy, as shown in
figure 2.2. The magnitude of this penalty is large (15-20 kJmol−1), and would always make
the fragment the most group efficient part of the molecule. Finally, the thermodynamics of
protein-ligand binding is affected by many factors on both the macroscopic and microscopic
level [157], making it difficult to attribute thermodynamic changes to change in structure.
Moving away from the use of affinity data, attention was turned to X-ray crystallography.
Fragment-bound protein crystal structures could be used to define the hotspot within a binding
site, however some special considerations would need to be taken into account. The size
of a hotspot may not match the size of the fragment bound to it, meaning a given fragment
may be able to match the shape and interactions of a hotspot, but also extend outside of it.
Secondly, as fragment concentration is very high during a crystallography experiment, it may
be that not all fragment binding sites are in fact hotspots. If a fragment is not bound to a
hotspot, fragment growth can lead to reorientation in the binding site [158]. Taking all of
this into account, for the purpose of this thesis, hotspots will be defined as follows:
Hotspots are the minimum binding site that will bind a fragment, maintaining the
fragment binding position once it has been elaborated.
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Fig. 2.3 3D Matched Molecular Pairs (MMPs) with insufficient data. Here, the smallest identified
compound makes up most of the final compound. Only four single atom additions can be identified,
resulting in a large sphere corresponding to the initial hit, with four small spheres for the single atom
3D MMPs.
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Table 2.1 Literature descriptions of protein environments that lead to unhappy waters, fragment
binding and hotspots
Name Protein Environment
Unhappy Waters (Young 2007) [130] A strongly hydrophobic cavity that encloses mul-
tiple water molecules or one to three hydrogen
bonds with the protein by the ligand, where the
remainder of the local environment is hydrophobi-
cally enclosed
Fragments (Ichihara 2014) [132] Fragment hits tend to displace water molecules
with notably unfavorable excess entropies— con-
figurationally constrained water molecules. This
is likely to be caused by confinement in hydropho-
bic pockets or a combination of hydrophobic en-
closure with hydrogen bonds
Hotspots (Kozakov 2015) [110] Concave topology combined with a mosaic-like
pattern of hydrophobic and polar functionality
2.1.3 Hotspot Environments
To predict the existence of hotspots, it is important to first understand the protein environments
that cause them. As discussed previously, fragment binding and high energy hydration
(unhappy water) sites occur at hotspots. A literature search for the protein environments
found at fragment binding sites, unhappy water sites and hotspots is summarised in table 2.1.
All three describe very similar situations:
• Hydrogen bond(s) pointing into an enclosed hydrophobic pocket
• Enclosed hydrophobic environment
The descriptions from Young and Kozakov are relatively brief, however Ichihara et
al.[132] made this the focus of their paper. They used WaterMap, the subject of Young’s paper
[130], to compare hydration sites displaced by fragments to those displaced during fragment
growing. They found that the most constrained hydration sites were always displaced by
fragments, rather than during the process of fragment growing. These were not exclusively
hydration sites that had a positive ∆G compared to bulk water, as typically thought of as an
unhappy water, but also included those that made a strong polar interaction with the protein.
This gave a very negative ∆H, resulting in a favourable change in free energy. Despite the
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favourable free energy of hydration, displacement of the water is possible if the ligand is
able to replace a geometrically strained water-protein hydrogen bond. This results in a large
entropy gain with minimal enthalpy loss. They reasoned that these hotspots are caused by
either water interacting with a hydrogen bond located within a confined hydrophobic pocket
or simply within a hydrophobic pocket. These environments will result in a reduced number
of available orientations of the water molecule, resulting in reduced entropy compared to
bulk water.
Water-centric approaches are computationally intensive, with calculations typically taking
24 hours. They are usually used once a binding site has been identified, rather than to
predict ligandable pockets. Vukovic and colleagues [159] have developed a method that
analyses clusters of high energy hydration sites as a means assessing ligandability, however
calculations can take days in addition to the initial 24 hour calculation.
The importance of solvation in the computational prediction of hotspots can be seen
from the evolution of computational methods. Early approaches such as MCSS[101] and
GRID[106] did not account for solvation, and found hundreds of false-positive minima across
the protein surface, in addition to the true-positives found experimentally [103, 105, 100, 121].
Sheldon Dennis and colleagues[160], the group that later developed FTMap, were the
first to produce a computational solvent mapping program that was able to reproduce the
experimental results. Importantly, their calculations included a desolvation energy term,
calculated using a continuum electrostatics model[161, 162]. In the development of FTMap
[123], they aimed to improve the speed of their sampling by using a fast fourier fransform
(FFT) correlation approach to sample a dense six dimensional translational and rotation
grid. This limited their scoring to sums of correlation functions, restricting them to simple
energy expressions. The energy expression they developed included terms for van der
Waals, electrostatics, a cavity term (to describe contribution of hydrophobic enclosure) and
a statistical pairwise potential (to represent other solvation effects). The latter two terms
provide a simplified description of how the protein environment affect solvation. Overall,
no loss in accuracy was found compared to their original implementation, and a six-fold
improvement in speed was achieved.
The approach described in this chapter aims to find the protein environments that cause
hotspots and unhappy waters. Buriedness measures and careful selection of probes will be
used to find these environments, removing the need for explicit water and MD, resulting in
faster calculations.
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2.2 Fragment Hotspot Maps Method
2.2.1 Overview
The Fragment Hotspot Maps method was developed in this project to make use of interaction
data in the CSD to identify hotspot-yielding environments from a static protein structure. The
method requires no prior knowledge of the binding site, performing a global search across
the whole protein to locate hotspots. The images in figure 2.4 show the output from the three
key stages of the fragment hotspots method, which can be summarised as follows:
Atomic propensity Mapping the propensities for atomic probes throughout
the protein (figure 2.4a)
Buriedness weighting Weighting the atomic propensities by the grid point’s
buriedness introduces the required enclosure (figure 2.4b)
Molecular probe sampling Final fragment hotspot map output (figure 2.4c). Sampling
the weighted propensities with molecular probes has two
important effects: eliminate pockets too small for frag-
ment binding, and locate polar interactions found within a
hydrophobic environment.
2.2.2 Atomic Propensities
The first step in the fragment hotspot map method is the calculation of atomic propensities.
This is done using existing software, SuperStar [115]. SuperStar uses Isostar data [114], a
library of intermolecular interactions in the CSD, to map the propensity for a given probe
type onto a 0.5 Å grid across the protein. The resulting propensities reflect how many times
more likely than random the given probe will be found at that grid point, based on interactions
in the CSD.
SuperStar requires the proteins to be protonated, and to have unimportant water or ligand
molecules removed. If any water or ligand is left within the protein, it is included in the
calculation and treated in the same manner as the protein. This is useful if there is a known
bridging water molecule that needs to be included in the calculation.
Normally the binding site would need to be defined prior to the SuperStar calculation;
however, no information about the binding site is used in this case. SuperStar uses the
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(a) SuperStar Maps (b) Weighted SuperStar maps
(c) Fragment Hotspot Maps
Fig. 2.4 Output maps at each stage of the Fragment Hotspot Map Calculation. Donor maps are shown
in blue, acceptor maps in red and hydrophobe in yellow. A fragment-bound structure (magenta, ligand
in sticks and protein hidden) has been aligned to the apo structure (white cartoon) for which the maps
were calculated, for reference. Taken from Radoux et al [1]
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LIGSITE [163] algorithm to detect cavities, and in the absence of a starting coordinate
or residue from which to grow the cavity, LIGSITE is run on the whole protein. It gives
each grid point a buriedness score between zero (completely solvent exposed) and seven
(completely buried). SuperStar then provides atomic propensities for cavities that contained
grid points with a LIGSITE score of five or above. The three maps shown in figure 2.4a were
generated using the SuperStar atomic probes listed below:
Hydrophobic Aromatic CH probe
Donor Uncharged NH probe
Acceptor Carbonyl oxygen probe
To find areas where high interaction propensity coincides with buried pockets, the
SuperStar maps are weighted by the LIGSITE score for each grid point. The weighted
SuperStar maps (figure 2.4b) begin to highlight the binding site, but still show propensity
throughout the protein. To find fragment hotspots, the weighted propensities are sampled
with molecular probes.
2.2.3 Sampling with Molecular Probes
As only hydrophobic, donor and acceptor maps are calculated, probes containing either all
carbons or carbons with a single donor or acceptor heteroatom are able to sample the maps
fully. The probes, shown in figure 2.5, were chosen to reflect hotspot environments. All
three probes have the same shape: the polar atoms represent a functional group attached
to the ring and toluene is used for the apolar probe. The large but flat rings are selected to
find tight hydrophobic environments, with polar interactions at the deepest part for the polar
probes. The probes may be too large to sample very small pockets accessible to alkyl chains
but were chosen as they resulted in fewer false positives when performing a global search.
Smaller probes could be used to give a deeper exploration of pockets highlighted by the
default probes. The bond orders of the probes are ignored, and it is just the atom types that
are used to assign a score from one of the three weighted SuperStar maps.
The probes undergo 200 rotations, which are uniformly distributed on the surface of a
sphere then translated such that they are centred on the heteroatom for the polar probes or
the methyl group of the toluene probe. All rotations of a probe are placed with their central
atom on the top 400 scoring grid points. Since the publication of the method’s validation
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Fig. 2.5 Three molecular probes used to sample the weighted atomic propensity maps. The bonds of
the probes are ignored and the atom types depend on the SuperStar probe used, in this case all yellow
atoms sample the aromatic CH propensity, the red atom samples the carbonyl oxygen propensity, and
the blue atom samples the uncharged NH2 propensity. The probe at the bottom shows an example of
how the probe score is calculated.
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[1], sampling has been modified to handle proteins of different sizes better. The most recent
method uses 1000 rotations and translates the probes to all grid points with a weighted
propensity greater than 17 (by default).
Calculation of the atomic propensities prior to sampling drastically reduces the number
of translations required. The total number of poses is in the range of hundreds of thousands
to millions, whereas FTMap is required to sample billions of poses[123].
For each pose, the atomic propensities are assigned to each atom from their corresponding
map. Any atom that clashes with the protein has a score of zero and the pose is skipped;
all remaining poses are assigned a score calculated by taking the geometric mean of their
atomic scores. Three 0.5 Å grids, one for apolar, donor, or acceptor atoms, are placed over
the protein. Each grid point that contains a probe atom is set to the score of the probe, not
including the carbon atoms for the polar probes. If multiple probes place atoms in the same
grid point, the highest score is used, giving the final output shown in figure 2.4c.
2.2.4 Fragment Hotspot Map Output
The resulting fragment hotspot maps are output as three grid files for each of the molecular
probes. The grids contain the scores of the molecular probes at each grid point, and require
an isosurface contour at a given score in order to be visualised. An example output is given
for CDK2 in figure 2.6, showing contours at 0, 13 and 18. A contour of 0 shows every grid
point that has been sampled by a probe, regardless of the score. At 13, the maps cover all of
the ATP binding site as well as several other pockets around the protein. Finally, a contour of
18 shows the highest scoring region of not only the protein, but also within the binding site
itself, picking out the interactions made by the fragment.
The scores themselves do not represent any measurable experimental value, but instead
describe how well a particular interaction or region resembles a hotspot yielding environment.
A high scoring region of the map represents a strong polar interaction (if applicable), found
in a highly buried and hydrophobic environment. Given the chosen definition of hotspot, the
highest scoring regions of the Fragment Hotspot Maps should match the fragment binding
site, with the high scoring polar interactions matching those made by the fragment. This
is demonstrated to be the case in figure 2.6, however this has been extended to a wider
validation set, covered in the next chapter.
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Fig. 2.6 CDK2 with Fragment Hotspot Maps at different score contours. The maps were calculated
for an apo crystal structure of CDK2, and a fragment bound structure (cyan) aligned to provide a
reference
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2.3 Conclusion
This chapter has discussed the key characteristics of small molecule binding hotspots, and
outlined the Fragment Hotspot Method, which aims to identify those environments. Literature
describing unhappy waters, fragment binding sites and hotspots each identified that the protein
environment at these sites provided hydrophobic enclosure, often with hydrogen bonds
trapping water molecules. The first computational method [160] capable of reproducing the
experimental results from MSCS, FTMap, improved upon existing methods by including a
desolvation term.
For Fragment Hotspot Maps, the effect of solvation is considered implicitly through the
inclusion of buriedness and selection of probes that identify environments shown to yield
unhappy waters [130], fragment binding [132] and hotspots [110]. The atomic interaction
propensities calculated by SuperStar are weighted by this buriedness term, and then sampled
by three molecular probes. The probe scores are used to generate the output Fragment
Hotspot Maps, with calculations taking around 10 minutes on three processors.
Fragment Hotspot Maps give a continuum of scores that can be contoured to give
different levels of description. Lower contours can describe whole pockets or warm areas,
while increasing the score contour will identify the hottest part of the binding site. The
chosen hotspot definition stated that fragments should bind to hotspots without changing
their binding pose upon elaboration. This defines how the method should be validated, which
will be discussed in the next chapter.
Chapter 3
Validation of the Fragment Hotspot
Maps Method
3.1 Validation Method
It is assumed that at least part of a fragment must interact with a hotspot in order to bind
efficiently enough to be both detectable by X-ray crystallography and to remain in place
upon elaboration. Fragment binding positions were therefore used as a standard for hotspot
prediction, with the understanding that it is possible that only part of the fragment will be
located within the hotspot. To discriminate between hotspots and the rest of the ligand binding
site, atoms from lead-like molecules were also examined and compared to the fragments.
The dataset collated by Ichihara et al. [132] contains crystal structures from fragment-
based drug design projects, where lead molecules developed from the fragment hit retain the
fragment binding position. Affinity data were available for each of the fragments and leads.
Here, this data set of fragment–lead pairs was extended further to include apo structures, on
which all calculations were performed, removing bias toward the binding site.
Protonated structures were retrieved from the Protoss server [164], which also protonates
the ligand using the context of the binding site where all waters and small molecules have
been removed. For each protein, the protonation was checked manually and then the fragment
and lead bound structures were globally aligned with the apo structure. Only the fragment
binding monomer was used.
Maps were created for all apo structures in the data set and scores assigned to both the
fragment and lead atoms. Each atom in the ligand was categorized as either hydrophobic,
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Fig. 3.1 Complete work flow for validation and calculation. Taken from Radoux et al [1]
donor or acceptor, and its score was read from the corresponding map. Sometimes the ligand
atoms were slightly displaced from a hotspot due to the alignment of the proteins and errors
in the crystal structure. To accommodate for this, the highest scoring grid point within two
grid points was assigned to the atom. Atoms that were in the maximum common substructure
match between the fragment and the lead molecules were assigned as “fragment atoms”, with
the remaining atoms assigned as “lead atoms”. The complete work flow for the validation is
summarised in figure 3.1.
3.2 Results
In addition to being able to highlight the fragment-binding site, the highest scoring inter-
actions predicted from the apo structure are often those made by the fragment; moderate
scoring interactions are picked up by the lead molecule. An example can be seen in figure
3.2, which shows HSP90 with a lead molecule developed by fragment linking. The portion
circled in blue coincides with the more potent of the two fragments and can be seen to occupy
the highest scoring region of the map (figure 3.2). Only one of the two acceptors is predicted
because the fragment binds to HSP90 via bridging water molecules, which were excluded for
the purpose of the validation. If a water molecule is known or predicted by other software
such as WaterMap [130] to be important for binding it can be included in the calculation.
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Fig. 3.2 (left) HSP90 with a lead molecule (magenta) and apolar (yellow to grey volume), donor (blue
surface), and acceptor (red surface) hotspot maps. (center) A closer look at the ligand with the protein
removed. (right) 2D schematic showing how the scores are distributed throughout the lead molecule,
with the primary fragment encircled in blue and the second in green. Scores are assigned based on
their atom type (e.g., acceptor nitrogen read from the acceptor map). Bright-yellow regions indicate
scores >17, purple indicates scores in the range 14–17, and scores lower than 14 are not highlighted.
The use of 17 or 14 is discussed below.
For HSP90, inclusion of the relevant water molecules allows identification the remaining
interactions of the fragment. The second fragment is shown to have a much lower score.
However, the crystal structure with both fragments bound shows it to stack on top of the first
fragment, likely contributing to its binding.
The results for all fragment and lead protein complexes are summarised in table 3.1 and
figure 3.3. In all cases, the average fragment atom score is greater than the average lead atom
score, and in most cases the highest scoring fragment atom was in the the 99th percentile or
greater of map scores.
The NS5 RNA polymerase fragment-binding site was the lowest scoring of the data set.
The highest scoring atom of the fragment only had a score of 8.6, as the fragment bound to
a moderately scoring region known as the thumb site, away from the large highly scoring
catalytic region described as the palm([165]). The fragment had the lowest experimentally
determined affinity out of the data set, in the mM range, and inspection of the electron density
showed that the fragment was poorly resolved. The temperature factors (B-factors) of the
fragment atoms ranged from 32 to 42 compared to the surrounding residue atoms, which
ranged from 12 to 24. This suggests that pockets should not be thought of as “hot or not”,
but rather a continuum, where moderate scoring regions are able to bind fragments, albeit
very weakly.
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Fig. 3.3 Overview of fragment and lead scores. (left) The highest scoring fragment atom (blue) and
lead atom (green) for each fragment-lead pair, labeled by their percentage ranking compared to all
grid points with a score greater than 0. At least part of the fragment is expected to interact with a
hotspot, therefore the highest scoring atom is used to determine whether the ligand is interacting
with a hotspot. Most fragments had their highest scoring atom in the top 1% of scoring grid points.
(right) Bar graph showing the (average lead atom score) – (average fragment atom score) for each
fragment–lead pair. In all cases, the fragment scores more highly than the lead.
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Table 3.1 Overview of datasets and results. The 2D structures of the leads have been mapped with
the atomic scores calculated from Fragment Hotspot Maps. Bright-yellow regions indicate scores
>17, purple indicates scores in the range 14–17, and scores lower than 14 are not highlighted. The
part of the molecule corresponding to the fragment is outlined in blue, and secondary fragments or
small molecules present in the fragment crystal structure that were later incorporated into the lead
are outlined in orange. Each image is titled by the protein name and accompanied by related PDB
codes, and the ligand efficiencies (LE) of the fragment (Frag LE) and the lead (Lead LE). PDB codes
labelled with * are structures with the natural substrate (unrelated small molecule inhibitor in the case
of JAK2), as an apo structure was not available.
Fragment PDB code: 2W1D
Lead PDB code: 2W1G
Apo PDB code: 4J8N
Frag LE: 0.60
Lead LE: 0.43
Fragment PDB code: 2OHM
Lead PDB code: 2OHU
Apo PDB code: 1W50
Frag LE: 0.33
Lead LE: 0.24
Continues on next page
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Fragment PDB code: 2V00
Lead PDB code: 2VA7
Apo PDB code: 1W50
Frag LE: 0.32
Lead LE: 0.36
Fragment PDB code: 2W70
Lead PDB code: 2W71
Apo PDB code: 2J9G*
Frag LE: 0.53
Lead LE: 0.41
Fragment PDB code: 1VYZ
Lead PDB code: 1VYW
Apo PDB code: 1HCL
Frag LE: 0.58
Lead LE: 0.41
Continues on next page
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Fragment PDB code: 2VTA
Lead PDB code: 2VU3
Apo PDB code: 1HCL
Frag LE: 0.54
Lead LE: 0.47
Fragment PDB code: 3CCB
Lead PDB code: 3CCC
Apo PDB code: 1J2E
Frag LE: 0.45
Lead LE: 0.54
Fragment PDB code: 2QFO
Lead PDB code: 2QG0
Apo PDB code: 1YES
Frag LE: 0.55
Lead LE: 0.30
Continues on next page
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Fragment PDB code: 3FT5
Lead PDB code: 3FT8
Apo PDB code: 1YES
Frag LE: 0.56
Lead LE: 0.39
Fragment PDB code: 2WI2
Lead PDB code: 2WI7
Apo PDB code: 1YES
Frag LE: 0.48
Lead LE: 0.33
Fragment PDB code: 3E62
Lead PDB code: 3E64
Apo PDB code: 4ZIM*
Frag LE: 0.56
Lead LE: 0.41
Continues on next page
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Fragment PDB code: 3FU0
Lead PDB code: 3FH7
Apo PDB code: 3B7S*
Frag LE: 0.21
Lead LE: 0.39
Fragment PDB code: 3CIZ
Lead PDB code: 3CJ5
Apo PDB code: 3MWV
Frag LE: 0.25
Lead LE: 0.31
Fragment PDB code: 1W84
Lead PDB code: 1WBT
Apo PDB code: 1WFC
Frag LE: 0.37
Lead LE: 0.32
Continues on next page
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Fragment PDB code: 1W7H
Lead PDB code: 1W83
Apo PDB code: 1WFC
Frag LE: 0.28
Lead LE: 0.27
Fragment PDB code: 3IMG
Lead PDB code: 3IUE
Apo PDB code: 3COV
Frag LE: 0.38
Lead LE: 0.29
Fragment PDB code: 1Y2B
Lead PDB code: 1Y2K
Apo PDB code: 3SL3
Frag LE: 0.48
Lead LE: 0.51
Continues on next page
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Fragment PDB code: 3ET0
Lead PDB code: 3ET3
Apo PDB code: 1PRG
Frag LE: 0.33
Lead LE: 0.31
Fragment PDB code: 2UW3
Lead PDB code: 2UW7
Apo PDB code: 4C33
Frag LE: 0.48
Lead LE: 0.45
Fragment PDB code: 2UVX
Lead PDB code: 2VO6
Apo PDB code: 4C33
Frag LE: 0.59
Lead LE: 0.48
Continues on next page
58 Validation of the Fragment Hotspot Maps Method
Fragment PDB code: 2VIN
Lead PDB code: 2VIW
Apo PDB code: 3OY5
Frag LE: 0.32
Lead LE: 0.32
The method aims to locate the interactions that drive fragment binding starting from a
global search of the protein. It is therefore important that the method avoids returning false
positive binding sites. Here it was assumed that the experimental binding sites from the data
sets are the only true positive binding sites, and any other sites detected were treated as false
positives.
During the calculation of the atomic propensities, the cavity detection process disregards
much of the protein surface. After sampling the atomic propensities with the molecular
probes and generating maps based on the highest scoring poses of each probe, the majority
of probes could only be placed within a small subset of cavities. To check whether the
fragments were found in the highest scoring regions, the atomic scores were compared only
to grid points that had at least one probe atom placed there. For each atom in the data set, its
score was ranked against all qualifying grid points of the protein that it was calculated from,
and was represented as a percentage rank.
Fragments were found to rank more highly than the lead atoms, with a median rank of 97%
compared to 72% for the lead atoms (those outside the fragment core). This demonstrates
that the Fragment Hotspot Maps are not simply locating ligand-binding sites but are picking
out the hotspot within those sites.
To aid with visualizing the output and assessing whether a hotspot is present, a cut-off
for a predicted hotspot was calculated. As it is possible that the fragment is larger than the
hotspot it binds to, the upper quartile of atomic scores for each fragment was used. The
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Fig. 3.4 Box and violin plots showing the percentage rank for fragment (green) and lead (pink) atoms.
An example fragment-lead pair within the Fragment Hotspot Maps is shown below the plot in the
same colours as the plot. The dotted line divides those atoms that contribute to the fragment from
those that contribute to the lead.
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Fig. 3.5 (left) PDE4 with a fragment in magenta and a lead molecule in cyan. The maps have been
contoured once at 14 (semitransparent) and again at 17 (almost opaque). Many of the fragment atoms
coincide with high scoring apolar (yellow) and acceptor (red) regions, suggesting these interactions
drive fragment binding. The cyan lead atoms and some of the fragment atoms extend into regions of
the pocket that only make the lower contouring level. The maps do not predict the NH of the fragment,
as it is facing the solvent. (right) At this contouring level, only the binding site contains any surfaces,
despite starting from a global search.
median of these values across the data set was 17, and the lowest was 14. Contouring at these
two levels allows visualization of not only where on the protein ligands are likely to bind
but also where within that pocket the fragment will bind and which interactions will drive
binding. This can be seen in figure 3.5, where areas of acceptor and apolar propensity >17
suggest the interactions leading to fragment binding, with areas >14 matching lead atoms
and remaining fragment atoms. Only the binding site of PDE4 contains maps scoring above
these contour levels; therefore this information does not come at a cost of being unable to
identify the binding site from a global search.
3.2.1 Protein Kinase B
Verdonk et al. [69] used a fragment growing approach to design inhibitors of protein kinase
B (PKB), and performed a Free–Wilson analysis to provide group contributions to binding.
They used GE, defined in equation 1.2, to evaluate whether a group increased potency
sufficiently to justify the number of heavy atoms it contained.
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(a) Inhibitor of protein kinase B labelled with the
group efficiency of each highlighted group [69]. (b) Fragment hit.
(c) Intermediate structure during fragment growth. (d) Full compound.
Fig. 3.6 Breakdown of PKB’s GE. Hydrophobic map in dark-grey to yellow shows moderate to high
scoring regions. Donor hotspots are shown as a blue surface, and acceptor hotspots are shown as a
red surface. The atoms seem displaced from the maps as the global alignment of the proteins did not
manage to align the binding site well.
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Their results are summarised in figure 3.6. The pyrazole is estimated to have a group
efficiency of 1.5, second only to the single-atom chloro group. Both the acceptor and the
donor interactions are predicted in the Fragment Hotspot Map, and the carbons are located
within the main hydrophobic hotspot. Comprising only five atoms, this small fragment binds
efficiently, as expected.
The first phenyl group does not make any specific interactions but is located mostly
within the main hydrophobic hotspot, reflected in a GE of 0.42. The methyl group has one of
the lowest group efficiencies of the groups, and was ultimately removed from the molecule.
From the maps, it can be seen to extend slightly outside of the main hotspot.
Addition of -EtNH2 to the phenyl ring yields one of the more group efficient additions to
the molecule. This is easily rationalized from the map in figure 3.6c, as the primary amine
occupies a region of high scoring donor propensity.
The second phenyl group is given a group efficiency of 0.28, which is the lowest of all
groups. This could be an underestimate, as addition of the phenyl group prevents the primary
amine from making the interaction it made previously, as can be seen in figure 3.6d. This is
one example out of many where addition of a group does not make a simple additive increase
in potency [166].
If the fragment binding site is known, it no longer makes sense to do a global search of
the protein unless additional binding sites are of interest. Instead, the calculation can be run
with the fragment included and the binding site defined to find nearby "warm spots". This
increases the speed of the calculation and limits the information to the cavities of interest to
the medicinal chemistry program. The run time for this calculation is only a few minutes on
a single processor.
The result of this calculation is shown in figure 3.7, where it is much more obvious which
direction the fragment should be grown in order to make the most efficient addition to the
molecule, with part of the phenyl group and the chloro group placed in highly scoring areas.
As the chloro group is a single atom placed in a highly scoring region, it is understandable
why it is the most group efficient addition. The chloro atom also affects the electronics of
the phenyl ring, and could again be an example where addition of a group does not lead to
simple additive increase in potency [166].
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Fig. 3.7 Hydrophobic Fragment Hotspot Map calculated with the fragment left in the binding site,
which was defined prior to the calculation. This allows for finer sampling of the pocket in much less
time as a global search of the protein is no longer needed.
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3.2.2 Pantothenate Synthetase
The lead molecule in this data set for pantothenate synthetase (PDB code: 3IUE) has been
recently revisited [167], and the group efficiency (GE) of each group determined to highlight
which part of the molecule should be developed further. Figure 3.8 shows how the GE is
distributed throughout the molecule and how each intermediate structure compares to the
Fragment Hotspot Map.
The fragment hit shown in figure 3.8b makes two specific interactions, the methoxy
oxygen matches an area of high acceptor propensity and the NH forms a hydrogen bond with
a sulfate ion. If the sulfate ion is included in the Fragment Hotspot Map calculation, then
the NH is located in a region of high donor propensity. However, although present in the
crystallization conditions, the sulfate is not present in the isothermal titration calorimetry
(ITC) measurement and therefore does not help rationalize the high group efficiency of the
fragment. It is possible that there is another ion in the ITC experiment that is able to bridge
the interaction in the same manner as the sulfate. One possibility is 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES), a buffer used in the ITC experiment. This is capable
of making the interactions of the sulfate ion, in addition extending into the second hotspot
(figure 3.9).
Addition of the sulfonamide moiety shown in figure 3.8c has a GE of just 0.17. This is
perhaps surprising as one oxygen of the sulfonamide is placed in a very high scoring region
and the NH forms a hydrogen bond with a bridging water molecule interacting with Gly-158.
This water molecule is displaced upon binding of the transition state analogue shown in
figure 3.11, so it is possible that this water is not particularly tightly bound, resulting in the
lower GE. The remaining sulfoxide and carbonyl oxygen atoms are left interacting with the
solvent, therefore again not contributing to the binding energy and reducing the GE.
The methylpyridine moiety added in figure 3.8d is also not very group efficient. The ring
occupies a moderately high scoring hydrophobic pocket but fails to satisfy any of the polar
interactions of the protein or the acceptor nitrogen of the pyridine.
The final addition of the ethanoic acid group is highly group efficient. The oxygen atoms
are placed in an area of very high acceptor propensity, resulting in a strong increase in binding
energy for a small increase in atom count.
From the GE analysis, the methylpyridine group was highlighted as the best place for
optimization. Toluene was found to be the most group efficient change, with a GE of 0.35
compared to 0.17. However, the crystal structures of the new more potent compounds showed
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(a) Group efficiency for the groups that make up the
lead molecule for pantothenate synthetase (PDB
code 3IUE) [167].
(b) Fragment hit (PDB 3IMG).
(c) Iteration of the hit-to-lead development used to
calculate the GE (PDB 3ISJ).
(d) Iteration of the hit-to-lead development used to
calculate the GE (PDB 3IUB).
(e) Iteration of the hit-to-lead development used to
calculate the GE (PDB 3IUE).
(f) Recent inhibitor of pantothenate synthetase
(PDB code: 4MUK), which fills the more highly
scoring P1 pocket.
Fig. 3.8 Breakdown of pantothenate synthetase’s GE. Hydrophobic map is shown in dark-grey to
yellow to show moderate to high scoring regions. Donor hotspots are shown as a blue surface, and
acceptor hotspots are shown as a red surface. The atoms seem displaced from the maps as the global
alignment of the proteins did not manage to align the binding site well.
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Fig. 3.9 Pantothenate synthetase with HEPES bound in place of the sulfate. This structure was created
by aligning the sulfate of HEPES to the sulfate ion found in the crystal structure. This results in the
HEPES molecule extending into the second hotspot.
that they no longer bound to the P2 pocket but instead bound to the P1 pocket, as shown in
figure 3.8e. The molecule was developed further by adding a trifluoromethyl group and an
extra carbon between the ring and the sulfonamide linker to completely fill the P1 pocket.
The molecule has a reported IC50 of 250 nM. As is clear in the figure, the P1 pocket is a
hydrophobic hotspot and is also capable of binding fragments.
The P1 pocket does have polar interactions available, but the lead molecule does not
interact with any of these. Looking again at the percentage ranking of atoms across the whole
data set, splitting the atoms into their corresponding interaction types shows the apolar atoms
to rank more highly than donor and acceptor atoms for both fragments and leads (figure 3.10).
In most cases, a few very highly scoring apolar regions correlated strongly with fragment
binding locations. Polar interactions were more likely to be left unsatisfied by the fragments,
but this does not mean they were unimportant for binding. The fragments in the data set were
typically flat and unable to match all the interactions highlighted by the Fragment Hotspot
Maps, exemplified in figure 3.11.
In contrast, when the maps were compared to a transition state analogue, almost all of
the predicted high scoring interactions were satisfied. This is in line with the findings by
Higueruelo et al [168], who used scissor plots [169] to describe the interactions of both
synthetic and natural ligands in proteins. Natural ligands were found to maintain a greater
ratio of polar to apolar contacts, with the number of polar atoms in the ligand correlating
with the number of polar contacts. In contrast, synthetic ligands tended to find a few polar
interactions with the remaining heteroatoms unmatched by the protein. For the lead atoms
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Fig. 3.10 Box and violin plots showing the percentage rank for fragment and lead atoms split by
interaction type. For both fragment and lead atoms, the apolar atoms are the most highly ranking.
Very few polar lead atoms were found to reside in highly scoring areas.
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Fig. 3.11 Pantothenate synthetase showing (left) two bound fragments in cyan (PDB code: 3img)
and (right) a transition state analogue in magenta (PDB code: 1n2h). Hydrophobic map is shown
in dark-grey to yellow to show moderate to high scoring regions. Donor hotspots are shown as a
blue surface, and acceptor hotspots are shown as a red surface. Although all the interactions of the
fragments are satisfied, they leave many of the protein interactions unsatisfied. The more 3D and
flexible transition state analogue satisfies the majority of interactions predicted by the Fragment
Hotspot Maps. One interaction not satisfied in either case is found to bind an ethanol molecule (in
magenta sticks), suggesting this is still a genuine hotspot interaction.
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in our data set, relatively few polar atoms scored above zero. This could be a physical
illustration of Hann’s [66] complexity constraint or the result of the tendency in medicinal
chemistry programs to add hydrophobicity to increase potency.
The two fragments bound to pantothenate synthetase each have two polar groups, both
of which are satisfied. When using X-ray crystallography for a primary fragment screen,
having a smaller library of simpler fragments like these is feasible as the elaboration of the
fragments can be visualized in three dimensions; the structural data allows complexity to be
built into the molecule to gain more affinity and selectivity by rational design during lead
optimization.
However, some opt for larger collections of more complex fragments, for which X-ray
crystallography is too low throughput. Pharmacophores derived from the Fragment Hotspot
Maps could make the use of X-ray crystallography with these libraries feasible. Rather than
relying on the promiscuity of simple fragments, the larger library could be filtered to give a
subset that matches the hotspot interactions of the target. This may yield higher quality and
more polar hits that would be more forgiving if hydrophobicity was then added to increase
potency.
3.3 Conclusions
Identification of hotspots and their specific interactions can be used to evaluate the ligand-
ability of a pocket and suggest which interactions fragments and larger ligands will need to
make to bind there. Current methods use hotspots to assess either ligandability of subpockets
from a global search of the protein [110], or provide interaction information for a predefined
binding site [143].
The Fragment Hotspot Maps method is capable of providing interaction information from
a global search of an apo protein crystal structure. As this method does not rely on MD,
results can be calculated within minutes rather than hours on an ordinary laptop. Ligand
atoms were consistently found in the highest scoring grid points; fragment atoms had a
median percentage rank of 97% and lead atoms 72%. In addition to being able to identify
fragment binding sites, the Fragment Hotspot Map method is able to highlight the interactions
likely to be made by fragments. This makes the method useful at multiple stages in the drug
discovery process.
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The maps will complement existing virtual screening methods. With the most important
interactions highlighted, existing pharmacophore methods can be used to screen for molecules
capable of making these essential interactions. Equally, the maps can be used to generate
constraints for docking, steering the docking toward occupying the hotspot and ensuring the
right interactions are made. Initially, this required the maps to be visually inspected and
then the docking constraints or structure-based pharmacophores to be generated manually,
however, automatic work flows will be discussed in the next chapter.
Chapter 4
Improving Accessibility and Integrating
with Existing SBDD Work Flows
4.1 Fragment Hotspot Maps Web App
4.1.1 Introduction
At the time of its publication [1], Fragment Hotspot Maps were calculated using a Python
script that could be run from the command line. The script required an input protein that
had been preprepared as described in chapter 2. It would generate a directory containing the
output files along with a second Python script to help display the results (example shown in
figure 4.1) in PyMOL [170], a Python-based molecular visualisation system. The PyMOL
session would display the Fragment Hotspot Maps as isosurfaces contoured at 17, 14 and 10,
values corresponding to "strong hotspot", "potential hotspot" and "binding site" as discussed
in chapter 3. Little user input was required to calculate and visualise the Fragment Hotspot
Maps, however the implementation limited who could run the calculations and how the
results could be used.
Many people are unfamiliar with working from the command line, or may not have
the required software (SuperStar and the CSD Python Application Programming Interface
(API)) to be able to run the calculations on their own computer. One of the strengths of
the Fragment Hotspot Maps method is the simplicity of the output, providing an easy-to-
interpret visualisation of hotspots that does not require expertise in CADD. In a post on
the Practical Fragments blog by Dan Erlanson [171] discussing Fragment Hotspot Maps,
Erlanson concludes with the following:
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Fig. 4.1 Example PyMOL session of results. Surfaces are pre contoured at 17, 14 and 10, with
hydrophobe maps set to yellow, donor to blue and acceptor to red
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"Unfortunately, as currently described, the process will require a skilled modeller. It
would be nice if the authors built a simple web-based interface for people to upload pdb
files for analysis, as is the case for FTMap."
A web application has since been developed to meet these needs. With the aim of making
the method as accessible as possible, the following requirements were set out:
• Inputs
– Enter a PDB code, then retrieve the structure
– Upload a PDB file
• Preparation
– Allow user to start from an unprocessed PDB file
– Give options to prepare the protein for calculation, such as adding hydrogens or
removing waters
– Default settings should reflect the most common usage
• Results
– Visualise the results through the web app, or download PyMOL session for future
use
– Basic functionality for changing protein representation, without cluttering the
interface
– Intuitive method for changing the isosurface contour level, which gives a clear
indication of what the score represents
4.1.2 Tools
Web development can be separated into two main areas: front-end and back-end. Front-end
refers to the creation of the web page that the user sees and interacts with. It is important
that the page is presented in such a way that the workflow is intuitive and consistent with
what the user is accustomed to. Luckily, frameworks such as Bootstrap [172] are becoming
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increasingly ubiquitous in front-end development. They help developers create professional-
looking and familiar interfaces, making navigation of a new website feel instinctive. Back-
end development refers to the logic, database interaction and calculations that occur in the
background. In the context of the Fragment Hotspot Maps web app, this will include the
retrieval and processing of PDB files, calculation of Fragment Hotspot Maps and storage
of the results. There are a variety of back-end programming languages available, including
python, which allows for easy integration with the Fragment Hotspot Maps scripts.
Pre-existing tools and frameworks allow scientists with limited web development ex-
perience to create intuitive websites within reasonable time frames. Further to this, freely-
available protein visualisation tools are available to be embedded into web pages, allowing
for results to be viewed directly on the website. Below is a list of the tools used in the
development of the fragment hotspots web app:
Pyramid A python-based web framework to run the back-end of the web-application.
This controls how the server responds to the user’s interaction with the site.
SQLalchemy A Python Structured Query Language (SQL) toolkit for interaction with the
database.
Jinja2 An HyperText Mark-up Language (HTML) templating language for use with
Python.
Bootstrap Open source HTML, Cascading Style Sheets (CSS) and JavaScript (JS) frame-
work for designing responsive and mobile-friendly web pages
jQuery A JS library to help with HTML document traversal, event handling and
animation.
NGL viewer [173] A WebGL-based web-application for molecular visualisation
4.1.3 Work Flow
This section will describe the process of running a Fragment Hotspot Maps calculation.
Each step will be described in terms of both the user experience, and work performed in the
background.
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4.1.3.1 Protein Input
User Experience Upon arrival to http://fragment-hotspot-maps.ccdc.cam.ac.uk/, the user
is greeted with the page shown in figure 4.2a. There are two options for uploading a PDB file:
Entering a valid PDB code, or uploading a valid PDB file. Optionally, the user can include a
name to find their results later. If a valid PDB code or file has been provided, clicking submit
will progress to the protein preparation page, else an error box will appear stating the PDB
code or file is invalid.
Background Work When a PDB code is used as input, the PDB’s File Transfer Protocol
(FTP) is used to retrieve the corresponding file. If a file does not exist, the input page is
reloaded with an additional message stating that the previous code was not found. Similarly,
when a PDB file is submitted the CSD Python API is used to parse the PDB file, if it is unable
to do so, an error is shown stating that the file is invalid. If the file or PDB code is valid, it
is saved to the hard disk in a newly created directory, and the CSD Python API is used to
ascertain which chains are present. A database entry is created for the job, and updated with
the location of the saved PDB file.
4.1.3.2 Protein Preparation
User Experience The user is presented with a few basic options, and the asymmetric unit
of their PDB file displayed in the NGL viewer, as shown in figure 4.2b. The first option is
a drop down menu with each of the chain identifiers. It is possible to select any number of
chains, and the protein’s cartoon representation has been coloured by chain identifier to aid
this selection. Tooltips are indicated by a " ?⃝", and hovering the mouse over them provides
helpful guidance without cluttering the page. For the chain select, the tooltip explains that
the user should not run the calculation on the whole asymmetric unit, but either the biological
unit or individual chains. After the chain select, there are two tick boxes to give options of
removing water molecules and adding hydrogens. These are set to "true" by default, but can
be disabled if the user has used alternative software to add hydrogens or wants to include
some water molecules in the calculation. Tooltips are used to explain when this is appropriate.
As the website is provided as a testing service, its computational power is limited and only
two jobs can be run simultaneously. Very large proteins can lead to large memory usage and
much longer calculation times, therefore a limit of 1000 residues has been put in place. If all
the selected chains exceed this limit, an error is given and the user returned to the upload
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page. Otherwise, submission of the options results in only a small delay as the protein size is
determined, followed by a redirect to the results table.
Background Work Once a PDB file has been loaded as a CSD python API protein object,
it is reasonably simple to manipulate the protein to match the user’s protein preparation
settings. Once the prepared protein has been saved, the fragment hotspot calculation is ready
to begin. There are two important considerations at this point. Firstly, the user’s browser
needs to still be responsive once the calculation has started. In order to achieve this, the
calculation needs to be done asynchronously, meaning a new process is spawned for the
calculation and the current process is allowed to redirect the user instantly to the next page.
Secondly, a queuing system must be implemented to allow several jobs to be submitted and
processed in order of submission, rather than all jobs running at the same time. The status
of each job is tracked in the database, and can be set to "Queuing", "Running", "Failed" or
"Complete". On submission of a new job, the number of running jobs is checked, if two are
currently running, the new job is placed in the queue.
4.1.3.3 Results Table
User Experience Upon submission of a job, the user will be directed to the results table
shown in figure 4.2c. The most recent job will be the first row of the table, and the status will
be set to either "Running" or "Queuing". The table refreshes automatically, and once a job is
completed the "view results" link becomes available and the next job in the queue is started.
The table has a search box, allowing the user to search for a previous result by filename or
user name.
Background Work The table is automatically updated through an Ajax (Asynchronous
Javascript and XML) request. This allows the data in the table to be refreshed every 5 seconds,
without having to reload the entire page. This process is only responsible for retrieving the
table data from the database, and does not start the next job itself as this would mean new
jobs only start when someone is viewing the results table. Instead, a server side process is
constantly running and checking the number of running jobs. Once the number of concurrent
running jobs goes below the maximum, the next job in the queue is started.
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(a) Start page. Upload a PDB file or enter a valid PDB code.
(b) Protein preparation page. Remove unnecessary chains, waters and add hydrogens if required.
Fig. 4.2 Using the Fragment Hotspot Web App
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(c) Results table page. All results are displayed here, once the calculation is complete, the "view
result" link will appear.
(d) Result page. Adjust the score contour with the slider, the maps change instantaneously with the
movement.
Fig. 4.2 Using the Fragment Hotspot Web App
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4.1.3.4 Result Page
User Experience The result page is shown in figure 4.2d. The left hand side of the window
contains a selection of buttons, check boxes, sliders and drop down menus to aid visualisation
and download results. The first two buttons allow you to create a high quality snapshot of
your current view, or download a PyMOL session file containing the results. There is a drop
down menu that allows the user to zoom and centre the view on one of the ligands found
within the crystal structure, and three check boxes to toggle lines, cartoon and waters from
the visualiser. The slider is used to control the contour level of the Fragment Hotspot Maps.
Movement of this slider updates the contouring level instantaneously, updating the maps
and the displayed score. To help the user understand what the score value represents, as the
slider is moved a description of the current score is updated. Based on the values discussed
in chapter 3, the scores are categorised as:
<10 Exposed interactions
10-14 Binding Site
14-17 Hotspot
17+ Strong hotspots
The right hand side shows the protein and Fragment Hotspot Maps displayed with NGL
viewer [173]. The user moves the slider to increasing score values until the Fragment Hotspot
Maps cover a "fragment-sized" volume in the binding site as shown in figure 4.3. At this
point, the value and the description from the slider can be used to assess the strength of the
hotspot. The viewer is "responsive", meaning that its dimensions will match those of the
window in which it occupies. This, in addition to the use of the Bootstrap framework, allows
the results to be viewed comfortably on mobile devices and tablets. This is demonstrated in
figure 4.3, where narrowing the window has caused the page to move to a vertical layout. The
page contains tooltips for further explanation of how to interpret the maps, without cluttering
the screen.
Background Work The interactive nature of the results page requires JS and jQuery. JS is
an event-driven language, meaning that code is executed in response to the user interacting
with the page. The NGL viewer is controlled through a JS API, allowing an event such as the
movement of the slider to update the contouring level of the Fragment Hotspot Maps.
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(a) Exposed interactions (b) Binding site
(c) Hotspot (d) Strong Hotspot
Fig. 4.3 Changing score contour with slider
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4.1.4 Conclusion
The purpose of developing this web application was to remove any barriers for running
Fragment Hotspot Map calculations. Providing the user has an input PDB code or file,
calculations can be run with two mouse clicks, and results can be inspected using a simple
slider to adjust the contouring level. As the contouring is adjusted, an assessment of the
hotspot is updated and presented to the user, making outcome of the calculation clear. As a
test of its simplicity, the web app was used by a group of second year undergraduates as part
of a workshop titled "Getting to know your target". The aim of this workshop was to assess
the tractability of a target, exploring data found in ChEMBL and the PDB as well as using
online computational tools. Given the example of CDK2, all students were able to run the
calculation and identify the hinge region as the ligandable site.
4.2 Hotspots API: Integration with the CSD Python API
Programming in science is becoming increasingly dominated by Python, a readable, general
purpose language that runs on all major operating systems. This has led to the development
of many specialist Python modules that allow users to perform complex tasks without having
to write much code themselves. The CSD Python API is an example of such a tool, providing
functionality to help with general handling of molecules and proteins, through to more CSD
specific uses:
• Molecular file input and output API
• CSD Entry API
• Molecule API
• Searching API
• Conformer API
• Protein API
• Docking API
• Screening API
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• Interaction API
• Descriptors API
• Diagram API
• Cavity API
The CSD Python API acts as a toolkit, Python scripts can be written to create work flows
tailored to the specific task at hand. This is particularly useful for dealing with large datasets,
where usage of a Graphical User Interface (GUI) would be repetitive and time-consuming
for the user. This section will cover how the Fragment Hotspot Maps methods were rewritten
as an API, and given functionality to create work flows that integrate well with the existing
features of the CSD Python API. This work was made possible by my colleague at the
CCDC, Richard Sykes. Richard is a Python developer, who has created much of the CSD
Python API, and created additional functionality to handle grid objects such as the Fragment
Hotspot Maps. This has greatly reduced the barrier for developing useful functionality for
the Fragment Hotspot Maps.
There are two ways in which a "Hotspots API" will improve the efficiency of working
with Fragment Hotspot Maps: How they are created, and how the results are utilised. The
original command line implementation required a fully prepared PDB file as input. This
required the use of other software, or running a separate CSD Python API script to first
prepare the protein. The Hotspots API aims to allow the user to run a calculation in a number
of ways from within a Python script, allowing both the preparation and calculation to be
executed in one go.
A general overview of the hotspots API is shown in figure 4.4. The region highlighted
in green shows the three methods available for running a fragment hotspot calculation. The
central feature of this schematic is the "Hotspot_results object", shown in red. This is the
result of the calculation, but requires further processing to generate a useful output. The parts
highlighted in blue show how the results can be utilised, and any number of these functions
can be used after Hotspot_results object is created.
4.2.1 Creating a Hotspot_results Object
There are three methods for generating a Hotspot_results object:
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Raw PDB file
Custom 
preparation of 
protein object
Hotspots.from_protein
Raw PDB Hotspots.from_file
Grid files from 
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calculation
Hotspot.from_grid_dic
Hotspot Results 
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Write 
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Set docking 
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Score protein 
atoms
Score ligand 
atoms
Score cavity 
features
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maps
Create field-based  
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Score 
Create ensemble 
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Output Virtual Screening
Combining 
maps
Fig. 4.4 Map of the Hotspots API. There are multiple methods for creating a Hotspot_results object
(red), with different starting inputs (highlighted in green) . Once this object has been created, there
are multiple functions available to utilise the results (highlighted in blue).
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From protein object Calculate fragment hotspot maps from a CCDC protein object. The
protein should have waters and ligands removed, and hydrogens added.
From PDB file Calculate fragment hotspot maps from a PDB file. Performs an initial faster
cavity detection, running several smaller calculations and combining the outputs of
each individual pocket. This is faster than running over the whole protein, but may
result in some smaller pockets being missed. By default, this will prepare the protein
by adding hydrogens, removing waters and ligands.
From grids Create a Hotspot_results object from a set of grid files. This allows all the
functionality of the Hotspot_results object to be used with previously calculated results.
The three methods represent the different scenarios in which a user is likely to run a
Fragment Hotspot Map calculation. Creating a Hotspot_results object from a file will be
most useful at the start of a work flow, with optional arguments to prepare the protein. The
user may also have previous results that they wish to revisit, and the "From grids" option
allows grid files to be loaded directly into a hotspot results object to give them access to the
functionality without waiting for the calculation to run once again.
Starting from a Protein() object allows the Fragment Hotspot Map calculation to take
place within a greater workflow. An example is given in figure 4.5, which shows the overall
process for a hotspot-guided docking run. This example starts with a GOLD docking
configuration file (conf file) as input. The conf file contains the settings from a previous
docking run, and loading it using the Docking API makes many of these setting accessible
through python, including the Protein() object. This protein object can be used directly to
create a Hotspot_results object, which is then used to highlight key hydrogen bonds in the
binding site to guide the docking.
4.2.2 Using the Hotspot_results Object
As discussed in chapters one and two, fragment binding sites can give information about both
the tractability of target and which interactions are likely to be essential within a binding site.
As the Fragment Hotspot Maps method is capable of predicting where fragments will bind
and which interactions they will make, this information can be used to help other CADD
methods. This section will take a look at the different ways the Hotspot_results object can
help streamline these work flows, concentrating on why each function will be useful and how
it was implemented. A case study will be explored in detail.
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Fig. 4.5 An example workflow for hotspot-guided docking
4.2.2.1 Output
Get output grids This function returns the output grids produced by the hotspot calculation.
These grids can then be saved to .acnt, .grd or .ccp4 files to be used later with other software
or loaded in another script to crate a Hotspot_results object.
Output PyMOL File Outputs a Python script to be run from within PyMOL to visualise
output. The function is flexible, and will allow the user to visualise anything that has been
calculated by the user for the Hotspot_results object. For example, if the user has generated
pharmacophores or results from a docking run, these can also be displayed in addition to
the Fragment Hotspot Maps. The function will load all required input files, and set up the
visualisation to be consistent with those generated in the publication.
4.2.2.2 Scoring
Each Fragment Hotspot Map is stored as a grid object, which contains functionality to lookup
values at any point on the grid. The following functions describe various applications for
reading the scores at a specific point in order to assign them to a given atom or feature.
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Score protein – Assigns a score to each protein atom from its corresponding map (polar
scores are taken from the partner atom type, i.e. a protein NH will get its score from the
acceptor map). For polar interactions, an ideal interaction partner position is defined, and the
highest scoring grid point within one grid point’s distance is assigned to the protein atom.
Donor scores are assigned to polar hydrogens, rather than the heavy atom. This is in line
with the assignment of GOLD hydrogen-bond constraints, and allows scores to be assigned
in cases such as a hydroxyl, which can act as a donor or acceptor.
Score ligand atoms – Assigns a score to each heavy atom based on type. For each atom,
the highest score is chosen from the nearest grid point and all surround grid points, to allow
for experimental error in the protein crystal structure. Returns a list of atomic scores. This is
most useful in situations where the user would like to implement their own scoring method
Score Ligand – As above, but returns the geometric mean of atomic scores.
Score cavity features – The cavity API gives access to binding site comparison methods
such as CavBase[174] and RAPMAD [175, 176]. The cavities are converted into a course-
grained representation where the exposed residues are converted to a set of pseudocentres:
hydrogen-bond donor, hydrogen-bond acceptor, mixed donor/acceptor, hydrophobic aliphatic,
and aromatic. This function assigns a score to each cavity feature from its corresponding
map. This uses the same approach as scoring the protein atoms, but instead returns the cavity
feature objects and their corresponding scores. This workflow will be discussed in detail in
the case study below
4.2.2.3 Combining Maps
Common mathematical and logic operators can be applied grid objects in the CSD Python
API. For example, g1 ∗−1 would multiply all points in grid g1 by -1 and g1− g2 would
subtract all points in g2 from g1. A prerequisite for mathematical operations involving
multiple grids is that the grids have the same size, shape and origin.
Selectivity map – Using a second Hotspot_results object created for an off-target protein
you wish to gain selectivity against, this function will return a new Hotspot_results object
that corresponds to high scoring regions present in the target protein, but not in the off-target
protein. The two proteins need to be aligned prior to the calculation, however this will still
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result in grids of different size, shape and origin. This function first modifies the grids such
that they have the same size, shape and origin, then subtracts the off-target grids from the
target grids.
Ensemble map - Takes a list of Hotspot_results objects created from aligned protein
structures and calculates the average maps across the ensemble. This will return a new
Hotspot_results object that has access to all of the same functions. Much like the selectivity
map, the grids from each protein are modified so that all maps across the set have the same
size, shape and location. The mean is calculated by summing the maps then dividing by the
number of proteins.
4.2.2.4 Virtual Screening
This final section describes some of the higher level functionality in the Hotspot API. These
functions coordinate more complex work flows, whilst still only requiring a few lines of
python from the user.
Write pharmacophore file – This function generates pharmacophore models from the
highest scoring regions of the fragment hotspot maps. Islands of propensity above the given
percentile (90th by default) are used to define pharmacophoric features. For polar maps,
the centroid of the pharmacophoric feature is set to the highest scoring grid point within
the island, for apolar maps, the feature is set to the centre of the island. Polar features
within 6 Å of a given apolar feature are assigned to that pharmacophore. As a result, several
pharmacophore files may be produced, corresponding to separate hotspots.
Predict protein H bond constraints – Takes a ccdc.docking.Docker.Settings instance and
adds protein H bond constraints to the top n scoring polar interactions, where n is the number
of constraints. A constraint instructs GOLD to penalise any docking pose that does not make
an interaction with the selected protein atom. This function makes use of the "score protein"
function to assign scores to each of the protein atom.
Ligand screener grids – Write out .acnt files that can be used by the ligand screener,
which will be covered in more detail in the next chapter.
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4.2.3 Case study: Hotspot-guided cavity comparison
An area of active research at the CCDC is storing and comparing protein cavities, using the
surface shape and interaction features of a binding site. The ability to compare a pocket of
interest to all other known pockets has fundamental applications in drug discovery:
• Identifying similar binding sites likely to give rise to toxicity or off-target effects
• De-convoluting polypharmacology
• Understanding the evolution of protein binding sites
• Elucidating the role of proteins of unknown function
• Mapping the plasticity of protein cavities in different apo and holo configurations
• Enhanced virtual screening ability
• Bioisosteric replacements of specific functional groups
Historically, sequence similarity has been applied to identify similar proteins; however,
this is largely limited to similarity arising from a common evolutionary starting point.
The comparison of binding cavity shape and features is much more powerful, but to date
experiments have been limited by computationally intensive calculations. Queries may take
from days to weeks to run, which restricts large scale calculations. New advances, however,
can reduce this time to minutes without compromising quality [175, 176].
Future work will use the Fragment Hotspot method to prioritise features within a cavity,
such that they are described by interactions that are highlighted as important for ligand
binding. Combining the Hotspot, Cavity and Interaction APIs will allow two research areas
to be explored.
4.2.3.1 Hotspot-guided cavity searching
Currently all cavity features, including those involved in hydrogen bonding with other protein
residues, are considered equally during a cavity comparison. One area to be explored is the
effect of reducing the features to include only high scoring interactions. A database of cavities
will be created and decorated with hotspot regions as described in figure 4.6, and previous
validation experiments will be repeated to assess the performance of cavity comparison
by prioritising the hot areas of the binding sites. Once a list of potential off-targets have
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Fig. 4.6 Hotspot-guided cavity comparison
been identified, selectivity maps can then be created to suggest how to avoid binding to the
off-target proteins.
4.2.3.2 Cavity vs ligand comparison algorithm
Changing focus to small molecules, FIMs[116] is a method based on SuperStar to gener-
ate maps that highlight the most frequent positions of interaction partners around a given
molecule, exemplified in figure 4.7. As with Fragment Hotspot Maps, the FIMs use probes
to show favourable donor, acceptor and aromatic probe positions. The peaks in the maps
surrounding the small molecule represent ideal binding interactions for the particular confor-
mation of the molecule, as predicted using interaction data in the CSD.
Reducing the cavity features to those likely to be involved in ligand binding may allow
cavity comparison methods to take a ligand as a query. As summarised in figure 4.8, the
peaks in the FIMs can be used to create a query binding site. This "binding site" can be
compared to the dataset of hotspot-guided cavities using existing cavity comparison methods.
This algorithm will be exploited to find putative binding sites from hits of phenotypic screens,
and molecules displaying polypharmacology.
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Fig. 4.7 Full Interaction Maps example, showing ideal positions for interaction partners based on data
in the CSD. Hydrogen bond donor show in blue, acceptor in red and hydrophobe in yellow
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4.2.4 Conclusion
The Hotspots API has provided a set of tools to grant greater flexibility in how Fragment
Hotspot Maps are created and used. It gives researchers access to functionality that would
otherwise be too time consuming to develop themselves as part of a wider project. This, in
addition to the web application, has greatly improved the accessibility and utility of Fragment
Hotspot Map calculations for people of all ranges of CADD and programming experience.
Some features of the Hotspots API have not yet been validated scientifically, such as the
hotspot-guided cavity comparison discussed in the case study, but have been developed in
order to enable future research. Other areas, such as virtual screening, have been looked at in
more detail, and will be discussed in the next chapter.
Chapter 5
Hotspot-Guided Virtual Screening
5.1 Introduction
For a small molecule to bind to a protein, there are several barriers that it must overcome.
Some are relatively simple, such as the need for shape and interaction complementarity,
however others are more complex. The ligand will face entropic penalties due to both its lost
ability to rigidly tumble and rotate[99], and loss of conformational and vibrational degrees of
freedom, which are more complex and typically require MD-based calculations[177]. Further
to this, both the ligand and protein may face internal strain as they assume conformations
suitable for the binding event. Any hydrogen bonds formed in the protein-ligand complex
must first displace water molecules on both the ligand and protein, which can have drastically
different effects on binding depending on their environment[132, 130]. Once the protein-
ligand complex has formed, both the resulting network of waters surrounding the solvent-
facing part of the ligand[178, 179] and the network of protein residues[180] have an impact
on the binding free energy. The quality of a resulting protein-ligand complex should not be
judged by the sum of its interactions[166], but rather by the overall free energy change of
the system starting from a fully solvated protein and ligand, and ending with the binding
complex. Although possible to predict computationally the absolute free energy of binding
for drug-like molecules while considering the system as a whole, it is only possible at huge
computational expense[181], 29 hours for each complex on 504 cores (Intel Xeon E5-2697
v2 2.7 GHz), and 7 hours on 372 cores for the ligand.
In early drug discovery, it is necessary to virtually screen hundreds of thousands of
molecules ahead of a primary screen. As a result, approximations are required to to allow
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for much more simple and computationally inexpensive methods that can handle such an
input. These methods do not seek to accurately predict the binding free energy of a complex,
but rather prioritise those compounds which are more likely to bind. There are multiple
approaches (table 5.1), depending on the type of data available, however they can be broadly
categorised as ligand-based or structure-based.
Ligand-based methods include both 2D and and 3D approaches. For 2D methods,
molecules are represented as binary bit strings (fingerprints), where each bit represents a
specific feature. Features present are set to 1, whilst those absent are set to 0. The similarity
between two fingerprints can be calculated using a number of methods, the most common
being the tanimoto coefficient [182] using equation 5.1 (C is the number of bits set in common
in the query and the database structure, Q is the number of bits set to on in the query structure,
and D is the number of bits set to on in the database structure). This can be used to query
databases of molecules to find those similar to known actives.
Although they are good at identifying close analogues, one limitation of 2D methods is
their inability to find novel chemistry capable of binding to the protein, exemplified in figure
5.1. This problem is circumvented in 3D ligand-based methods such as pharmacophoric
screening, as the structures of actives molecules are turned into abstract pharmacophoric
features (figure 5.2 created using Pharmit[183]). A match will be returned providing the
database molecule is able to place matching atoms with each of the spheres, however
the definitions of a match can be much looser and the scaffold connecting the functional
groups can be completely different to the query molecule. A downside to ligand-based
pharmacophoric screening is that it relies on having a conformation close to the bound
conformation, requiring either a protein structure containing the active ligand or the use of a
ligand overlay program[184] in conjunction with multiple actives.
It is also possible to generate pharmacophores using the protein structure, but choosing
which interactions to use can prove difficult for novel pockets. As described in the previous
chapter, it is possible to create pharmacophores from the Fragment Hotspot Maps themselves,
shown in figure 5.3. By creating pharmacophoric features for just the interactions in the
hotspot, the pharmacophore model can search for molecules that satisfy these essential
interactions. Once a hit is found, the ligand can be scored in the Fragment Hotspot Map
to identify how well the rest of the molecule matches the interactions. A big benefit of
pharmacophore screening is speed, Pharmit is able to screen millions of molecules within
seconds to minutes[183], depending on the complexity of the query. The use of hotspot-
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Fig. 5.1 Tanimoto coefficients calculated between Morphine and Codeine, Heroin and Methdone.
Table 5.1 Virtual screening methods
Method Category Example
Docking Structure-based GOLD[185]
Pharmacophore searching Structure and/or ligand-based Phase[186]
Shape-based screening Ligand-based ROCS[187]
2D Similarity searching Ligand-based Review of methods by Sheri-
dan and Kearsley[188]
derived pharmacophores is ongoing research for another PhD student at the CCDC, Peter
Curran, so will not be discussed in this chapter.
SimilarityQD =
C
Q+D−C (5.1)
The more complex barriers to binding discussed at the start of this chapter are typically
too difficult to include explicitly in virtual screening. One exception is WScore in Glide
docking[189], which uses the results from a WaterMap calculation to give a flexible de-
scription of explicit water molecules, leading to improved docking performance. While
WScore uses MD-based WaterMap calculations to calculate the thermodynamic properties of
hydration sites, a more simple approach will be taken here. Fragments are able to overcome
all of these barriers despite having a limited binding interface with the protein, making highly
efficient interactions at the hotspot. As these interactions also make a disproportionately
large contribution to the free energy of binding in larger molecules, it is important that
virtual screening methods favour making these interactions over others. In the absence of
96 Hotspot-Guided Virtual Screening
Fig. 5.2 A ligand and its corresponding pharmacophores
fragment-bound crystal structures, interactions at predicted fragment binding sites can be
used.
This chapter will look at two virtual screening methods, and how information from
Fragment Hotspot Map calculations can have an impact. The first approach will use docking
with GOLD[185], and use the "predict protein H-bond constraints" method discussed in
the previous chapter. The second approach looks at using a field-based virtual screening
tool, which was designed as a 3D ligand-based tool, but has been modified to take Fragment
Hotspot Maps as a direct input.
5.1.1 Docking with GOLD
Docking programs consist of two main parts: a method for sampling poses and a method
for scoring these poses. Generation of ligand poses involves sampling its rotational and
translational degrees of freedom as well as its conformational degrees of freedom. Brute
force sampling is far too slow and would spend a lot of time sampling high energy struc-
tures, therefore methods have been developed to have reduced but more relevant sampling.
While one of the earliest docking programs, DOCK[190], used rigid ligands to avoid this,
GOLD[185] uses a genetic algorithm (GA) to allow full ligand flexibility.
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Fig. 5.3 CDK2 with pharmacophores generated from Fragment Hotspot maps and ATP displayed as
sticks. Only the polar maps have been displayed for clarity.
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As the name suggests, a GA requires a starting population that "evolves" to give the output
poses. A ligand’s rotatable dihedral angles and protein-ligand hydrogen bonds are represented
as genes, which can undergo genetic operations. The collection of genes for a given pose
is called a chromosome, and each chromosome is assigned a fitness score. Two parent
chromosomes are selected, with a bias towards to those with greater fitness scores. Genetic
operators are applied (crossovers, mutations and migrations) to the parent chromosomes and
a new structure is generated. The number of inter-molecular hydrogen bonds are maximised
using a least squares fitting protocol. The final structures are then ranked with a more
complex scoring function. Since the original GOLD publication[185], hydrophobic fitting
points have also been included as part of the least squares fitting protocol[191].
When performing a docking calculation on a pocket with known actives, it is possible
to steer the docking towards the correct answer by using docking constraints. A protein
hydrogen bond constraint will place a penalty to the fitness of a pose that does not make
a hydrogen bond to the selected protein atom. This will not only favour the ranking of
molecules that make the chosen hydrogen bond, but also guide the GA sampling to guide
solutions towards those where the chosen interaction is made.
The importance of docking constraints is exemplified by the docking of S-adenosyl-L-
homocysteine (SAH) into MLL1. SAH (figure 5.4) is a very flexible molecule, with 11
non-terminal rotatable bonds, and the pocket of MLL1 is very open, making this a difficult
case. Under the default setting, GOLD is unable to correctly place the amino and carboxylate
groups of SAH (figure 5.5a). Although the core of the molecule is correct, there is insufficient
sampling for the flexible "tail" of the molecule to find the interaction. One solution is to
greatly increase the sampling performed by GOLD, which is able to bind the correct pose,
however the calculation time increases from approximately 3 minutes to over 15 minutes.
Calculation of Fragment Hotpot Maps for MLL1 produces the output shown in figure 5.5d
when contoured at 17. These are the only three interactions highlighted across the whole
protein, with the region of blue donor propensity giving the highest score. Adding the
histidine nitrogen as a constraint yields the correct pose within 3 minutes, as shown in figure
5.5c. Identification of the correct binding pose is important in virtual screening as it is
required to correctly assess the ligand.
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Fig. 5.4 Structure of S-adenosyl-L-homocysteine (SAH)
5.1.2 Field-Based Ligand Screener
The field-based ligand screener is part of a larger ligand-based virtual screening workflow. In
cases where a protein structure is absent, but multiple actives are known, it is possible to use
this information to do 3D ligand-based virtual screening with the assumption that they bind
to the same part of the protein. The workflow can be summarised as follows (see also, figure
5.6):
1. Generate 3D coordinates and enumerate conformers of active molecules.
2. Use the Ligand Overlay tool[184] to flexibly align common features of the conformers,
aiming to generate a model for the bound position of the actives
3. Generate a field-based pharmacophore model to represent the common features of the
actives. The Ligand Screener can then sample the fields with a library of molecules,
scoring them with the values from the fields.
This section will explore the standard workflow for ligand-based virtual screening, and
section 5.2.3 will use this context to explain how the Fragment Hotspot Maps can be inserted
into this workflow.
5.1.2.1 Conformer Generation
The CSD conformer generator takes an input 3D molecule, and makes use of structural data
in the CSD to generate a realistic ensemble of low energy conformers. The CSD can be used
to generate libraries of bond lengths, valence angles and rotamers[192]. These libraries are
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(a) Default GOLD settings
(b) Extra sampling (c) Hotspot-derived constraints
(d) Crystal structure with Fragment Hotspot Maps contoured at 17 (apolar hidden for clarity)
Fig. 5.5 Docking SAH into MLL1. Images (a), (b) and (c) taken from the GOLD tutorial, docked
poses in green, crystal poses in grey.
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Fig. 5.6 Ligand-based virtual screening workflow. (Top) Conformer generation, (middle) ligand
overlay and (bottom) field-based ligand screener. Adapted from the CCDC Ligand-based virtual
screening tutorial
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applied to a fragmented view of the input molecule and assigned an approximate probability
score based on how frequently such a geometry is observed in the CSD. As a conformer is
incrementally generated, it is checked for clashes and rejected as soon as a clash is detected.
The conformers are clustered by conformer similarity, and a diverse set returned. The CSD
conformer generator is available through the CSD Python API, and readily incorporated into
greater workflows
5.1.2.2 Ligand Overlay
The ligand overlay application[184, 193] takes a set of active molecules, and aims to flexibly
align them such that ligand groups that interact with a given protein residue are superimposed.
In the absence of a protein structure, this model can give information about the binding site
shape and key interactions.
Each ligand is annotated with features, such as hyrdophobe, strong donor, medium
acceptor etc, which are described by a set customisable smiles arbitrary target specification
(SMARTS) strings. Once the features have been identified, fitting points are placed either at
the location of the heavy atoms or the centroid of a set of atoms, depending on the feature
type. The overlays are represented as fingerprint called a chromosome, as described above
for sampling with GOLD, and bit-string manipulations are applied to these fingerprints
to generate thousands of overlays. These overlays are subsequently scored using three
functions, union volume, hydrogen bond match, and hydrophobic match. They are ranked by
constrained Pareto ranking, and the top twenty overlays of a diverse subset of the solutions
are returned.
5.1.2.3 Ligand Screener
The ligand screener uses a set of overlaid molecules to build a grid-based pharmacophore
model, which it then uses to screen a library of molecules. The overlaid molecules can come
from the ligand overlay application described above, but can also come from a set of aligned
protein-ligand crystal structures. Each atom is assigned a feature type (strong donor, medium
donor, weak donor, strong acceptor, medium acceptor, weak acceptor, donor-acceptor and
non-polar), much like in the ligand overlay program. Once all the features are assigned, a
field potential is created for each feature type by placing a gaussian distribution at each atom
location. The resulting grids reflect how frequently a given interaction type is found at each
position, and larger sets of actives can give a better idea about which interactions are more
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important for binding. In addition to this, an excluded volume penalty is also created for grid
points greater than 3 Å away from any atoms in the overlay.
Fitting points are created from the model, and a global optimisation of the translation
and rotation is performed to fit conformers of the library ligands. Customisable rules allow
the user to weight the scoring of a match, for example between a "medium donor atom"
from a screened ligand to a "strong donor fitting point", as well as penalties for mismatched
placements. The best scoring pose it used for each ligand, and a ranked list returned.
5.1.3 Metrics
There are multiple ways to assess the performance of virtual screening methods. The results
discussed within this chapter will use metrics suggested by Jain and Nicholls [194], receiver
operating characteristic (ROC) curves in conjunction with area under curve (AUC) and
enrichment factor (EF) calculations. ROC curves are a type of plot that is used to assess
a binary classifier system, in this case the ability of a virtual screening method to classify
molecules as active or inactive. An example ROC curve is shown in figure 5.7, and this
particular example shows a method that is capable of retrieving active molecules more
successfully than a random selection, demonstrated by the green curve being above the
random line. The AUC of the random line is 0.5, therefore any value greater than 0.5 shows
improvement.
One criticism of using AUC as a virtual screening method is that it is a global measure.
In reality, the typical usage of a virtual screening workflow is to take the top x% of the ranked
list to confirm with experimental screening. A successful virtual screening tool should enrich
the top n% with active molecules, and the enrichment factor, described by equation 5.2, gives
a measurement of this enrichment. Nexperimental describes the number of actives found after
virtual screening, Nactive is the total number of actives in the library and x% is the percentage
of the library screened.
EF =
Nexperimental
Nactive · x% (5.2)
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Fig. 5.7 Example ROC curve. The dotted line represents the performance of a random selection. False
Positive Rate (FPR) is on the x axis, and True Positive Rate (TPR) on the y axis. While the green line
is above the random line, the method is performing better than random
5.2 Method
In the rest of this chapter, we will assess how the scores from Fragment Hotspot Maps can
be used to aid virtual screening. The first approach will assign a docking constraint within
GOLD to the highest scoring polar interaction, placing a penalty on all ligand poses that do
not interact with the selected protein atom.
5.2.1 Dataset
When evaluating a virtual screening method retrospectively, decoy molecules are screened as
well as known actives, and the virtual screening method is assessed on its ability to rank the
compounds such that the actives are on top. Extra special care must be taken when choosing
active and decoy molecules. If the properties of the decoy molecules are different from the
actives, the docking program may display artificially good performance. The directory of
useful decoys - enhanced (DUD-e) set[195] provides a dataset of targets with diverse actives
selected from ChEMBL, and property matched ligands from the ZINC database[196] as
decoys. The full dataset contains 102 proteins, 22886 clustered active ligands from ChEMBL,
each with 50 decoys from ZINC. As this work aims to be a preliminary look into the effect of
using hotspots to guide virtual screening, the full set will not be used, but instead the diverse
subset will be used (table 5.2). Each protein was protonated using protoss[164], with all
waters and ligands removed (cofactors such as the heme group of CP3A4 are kept).
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Table 5.2 Diverse subset of DUD-E
Target Name PDB Description Actives
AKT1 3cqw Serine/threonine-protein kinase AKT 293
AMPC 1l2s Beta-lactamase 48
CP3A4 3nxu Cytochrome P450 3A4 170
CXCR4 3odu C-X-C chemokine receptor type 4 40
GCR 3bqd Glucocorticoid receptor 258
HIVPR 1xl2 Human immunodeficiency virus type 1 protease 536
HIVRT 3lan Human immunodeficiency virus type 1 reverse transcriptase 338
KIF11 3cjo Kinesin-like protein 11 116
5.2.2 Hotspot-Guided Docking
Following the workflow described in the previous chapter’s figure 4.5, the Hotspot API was
used to calculate the Fragment Hotspot Maps, and the "predict protein H bond constraint"
function was used to assign a constraint to the highest scoring polar interaction. The
ChemPLP scoring function[197] was used, as it has previously been identified as the best
scoring function for virtual screening[198] and is now the default scoring function in GOLD.
For each ligand, 15 docks were permitted, and all other settings were left as the default.
The docking calculations were performed twice for each protein, both with and without the
protein H bond constraint. As this work aims to treat pockets as completely novel, only the
automated optimisation of the hydrogen bonding network by Protoss was performed, and no
other adjustments were made to the protein residues.
5.2.3 Hotspot Field-Based Screening
A crucial step in the standard ligand-based virtual screening workflow is the generation of
field potentials to describe where ligand atoms are most often placed in the overlay. In the
screening API, the only input allowed for the ligand screener is a set of overlaid ligands, and
these field potential grids are only created as an intermediate step. Modifications made by
Jason Cole, a colleague at the CCDC, allowed the calculations to be performed starting from
the field potential grids. Although Fragment Hotspot Maps can be easily saved in the same
file format as those required by the ligand screener, modifications needed to be made in order
to use the Fragment Hotspot Maps in place of the normal field potentials:
Problem Polar interactions have three map types: strong, medium and weak
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Solution Three grids for each polar probe are created. The strong grid contains grid points
at the 95th percentile, the medium grid at the 60th percentile, and weak at the 30th
percentile
Problem A donor_acceptor grid is required for atoms that can be both a donor and acceptor
Solution A donor_acceptor grid is created which includes all grid points where both the
donor and acceptor score is greater than 14
Problem Favourable interactions are given negative scores, unfavourable are given positive
Solution The Fragment Hotspot Maps are multiplied by -1, and normalised such that the
highest scoring grid point is -6, -3 or -1 depending on whether it is a strong,
medium or weak grid. Non polar and donor_acceptor grids are treated as medium.
The "strong" grids represent the highest scoring regions of the polar fragment
hotspot map, and are weighted more favourably in the scoring step during screen-
ing. Unfavourable scores are not included, other than the excluded volume penalty
Problem Each grid needs an excluded volume penalty
Solution The ligsite grid is used to define which grid points clash with the protein. Any
grid point with a ligsite score of 0 is given a score of 10 (unfavourable), otherwise
the point is set to 0. A smoothing function is applied to give a gradient of scores
from 0 to 10. The resulting excluded volume grid is added on top of all other grids
The modified grids (figure 5.8) are saved into a single directory with the correct file names,
as required by the ligand screener tool. The final step is to provide conformers from the
screening library. Using the CSD conformer generator, 25 conformers for each ligand were
produced and screened. Previous unpublished worked showed that the using the default 200
conformers gives no improvement in performance. The values chosen above (percentiles and
normalisation scores for strong, medium and donor) were selected as reasonable estimates
for this proof of concept work, and have not been optimised. This approach will be referred
to as the hotspot-based ligand screener (HS-LS) approach
In addition to using the Fragment Hotspot maps as input, the same experiment has been
performed by Pete Curran, a fellow PhD student at the CCDC, using ligand bound protein
crystal structures from the PDB. Using the crystallographic overlay represents the best case
scenario, these results represent the best performance from the ligand screener tool regardless
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Fig. 5.8 A cross-section of a strong acceptor ligand screener grid generated from the acceptor fragment
hotspot map. The colours represent favourable positions (blue) and unfavourable positions (red) for
acceptor atoms.
of the quality of input. This method will be referred to as the PDB overlay ligand screener
(PDB-LS) method. Curran performed a second run, having first removed crystal structure
ligands that have a Tanimoto similarity ≥ 0.7 to the actives. This tests the ligand screener’s
ability to retrieve novel chemistry, and will be referred to as the novel PDB overlay ligand
screener (nPDB-LS) method
5.3 Results and Discussion
Each virtual screening run for each target was run on a single processor. The time taken
for each calculation varied based on the number of ligands to be screened, but the ligand
screener was approximately 4 times faster than docking (9 hours vs 35 hours for KIF11). The
following two sections will give an overview of the results for each of the methods, before
taking a closer look at each target.
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Table 5.3 Docking AUC
Target Docking Constraint Change
akt1 0.78 0.79 +0.01
akt1 penalty=100 0.78 0.84 +0.06
ampc 0.52 0.57 +0.05
cp3a4 0.63 0.63 0
cxcr4 0.62 0.62 0
gcr 0.56 0.57 +0.01
hivpr 0.75 0.76 +0.01
hivrt 0.68 0.71 +0.03
kif11 0.81 n/a n/a
Average 0.67 0.68 +0.01
5.3.1 Hotspot-Guided Docking Overview
The AUC values for docking with and without constraints are shown in table 5.3. It is
clear from the table that there is only a modest improvement in AUC upon addition of
the constraint. This might suggest that the default penalty for missing the selected protein
hydrogen bond may have been too weak. In order to investigate whether a larger penalty
would have further improved the results, AKT1 was run a second time with a penalty of 100.
This resulted in a much larger improvement in both AUC and EF, demonstrated by the ROC
curve in figure 5.9d. Due to the time required to run these calculations, it was not possible to
repeat this for further targets.
As discussed previously, AUC is a global measure and EF more closely reflects the use
of virtual screening in drug discovery. Enrichment at 1% is given in table 5.4, and shows
improvement across all targets with non-zero enrichments. The two targets with EF = 0
have failed to find a single active in the top 1% of compounds screened, however these two
targets have a much smaller number of decoys and ligands. As a result, the EF1% is a less
significant value for these targets, and EF10% (table 5.5) is more suitable. EF10% showed
much smaller changers upon addition of the constraint, resulting in improvement for four
targets and a reduction for two targets.
5.3.2 Hotspot Field-Based Screening Overview
AUCs for the three ligand screener experiments are shown in table 5.6. The "PDB-LS"
column represents the best case scenario for the ligand screener, whilst the "nPDB-LS"
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Table 5.4 Docking Enrichment at 1%
Target Docking Constraint Change
akt1 9.90 12.73 +2.83
akt1 penalty=100 9.90 15.70 +5.80
ampc 0.00 0.00 0
cp3a4 4.12 7.06 +2.94
cxcr4 0.00 0.00 0
gcr 5.04 8.52 +3.48
hivpr 12.50 15.30 +2.80
hivrt 5.33 7.10 +1.78
kif11 17.24 n/a n/a
Average 6.77 8.71 +1.94
Table 5.5 Docking Enrichment at 10%
Target Docking Constraint
akt1 5.32 5.10 -0.22
akt1 penalty=100 5.32 5.94 +0.62
ampc 1.46 1.25 -0.21
cp3a4 2.65 2.82 +0.17
cxcr4 0.75 1.00 +0.25
gcr 3.14 3.14 0
hivpr 4.55 4.72 +0.17
hivrt 2.63 3.08 +0.45
kif11 6.21 n/a n/a
Average 3.34 3.42 +0.08
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Table 5.6 Ligand Screener AUC values. The "HS-LS" column has used modified Fragment Hotspot
Maps as input, the "PDB-LS" column has used an experimental overlay as input, and "nPDB-LS" has
used a subset of PDB ligands dissimilar from the actives in the test set. Cells with n/a show cases
where no PDB ligands remained after the similarity cut off was applied
Target HS-LS PDB-LS nPDB-LS
akt1 0.72 0.72 0.72
ampc 0.52 0.76 0.76
cp3a4 0.57 0.60 0.52
cxcr4 0.70 0.72 n/a
gcr 0.82 0.87 0.73
hivpr 0.79 0.87 n/a
hivrt 0.50 —- 0.50
kif11 0.81 0.91 0.91
column reflects the ability to retrieve novel chemistry. The HS-LS results tend to yield
similar AUC values to the PDB overlay, and in some cases have better AUC values than
nPDB-LS results.
Enrichment factors at 1% show varying performance between targets. There are large
enrichments from both PBD overlay runs for gcr, hivpr and kif11, but these are not achieved
by the HS-LS runs. Closer inspection of the ligand screener grids created from the PDB
overlays showed that there was a much larger range of scores than the normalised scores
created from the fragment hotspot maps. While the hotspot grids were normalised to be in
the range of -6 to 0, the PDB overlay for kif11, the target with the best EF, resulted in a score
range of -29 to 98 for the strong acceptor and -25 to 90 for the strong donor grids. In contrast,
the worst performing PDB-LS run was cp3a4, which had a score range of -9 to 16 for the
strong acceptor and -4 to 17 for the strong donor grid. In order to achieve the EFs of the PDB
overlay methods with the hotspot input, it is likely that a greater score separation is required
between the interactions found at the 95th percentile, 60th percentile and 30th percentile. It
may also be necessary to implement penalties for mismatched hydrogen bonding groups.
This would require identifying grid points with a high score for one polar probe, but a low
score for the other. As a result, favourable regions on the donor maps would appear as
penalties on the acceptor maps, and vice-versa.
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Table 5.7 Ligand screener Enrichment at 1%
Target HS-LS PDB-LS nPDB-LS
akt1 7.09 7.09 0.71
ampc 0.00 8.06 4.84
cp3a4 2.75 2.20 2.48
cxcr4 0.82 2.46 n/a
gcr 3.55 21.85 17.76
hivpr 8.67 21.00 n/a
hivrt 1.10 —- 2.03
kif11 5.08 25.89 20.30
Table 5.8 Ligand screener enrichment at 10%
Target HS-LS PDB-LS nPDB-LS
akt1 3.10 2.55 2.65
ampc 1.46 4.52 3.39
cp3a4 1.79 1.82 1.07
cxcr4 2.05 2.38 n/a
gcr 3.80 5.68 3.23
hivpr 4.14 5.87 n/a
hivrt 1.19 —- 1.33
kif11 3.55 6.50 6.45
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5.3.3 AKT1
Serine/threonine-protein kinase AKT (AKT1) gave the second best AUC and EF for docking,
and the fourth best AUC (second for EF) for the ligand screener. Introduction of the
default constraint for docking gave a moderate improvement in AUC, but did see a larger
improvement in EF 1% (9.9 to 12.7). The resulting ROC curves for with (figure 5.9b) and
without (figure 5.9a) the hotspot derived constraint show little difference, however increasing
the penalty to 100 gives a noticeably steeper curve. Inspection of the Fragment Hotspot Maps
and the selected protein atom for constraint, shown in figure 5.9e, shows that the selected
interaction is the backbone NH of the kinase’s hinge.
The ligand screener achieved both a slightly lower AUC and EF 1%. Although the AUC
was the same for all three ligand screener inputs, removal of PDB ligands similar to those in
the active set led to loss of enrichment at 1%. This suggests that using the ligand screener
with Fragment Hotspot Maps as input is better at discovering novel chemistry than the PDB
overlay in this case.
5.3.4 AMPC
Beta-lactamase (AMPC) was one of the most challenging targets for either of the virtual
screening methods. They offered almost no improvement over random selection for docking
(figure 5.10a) or the ligand screener figure 5.10c. Addition of the hydrogen bond constraint
to the amino group of asparagine 152’s carboxamide leads to improvement in AUC from
0.51 to 0.57. Despite the improvement in AUC, this still results in an EF of 0, meaning no
actives were found in the top 1%. This is not too surprising, as AMPC only has 48 actives.
Using equation 5.2, a single active found in the top 1% would give an EF of 2.08. For so few
actives, it is more meaningful to take the EF at 10%, which in this case gives 1.46 for normal
docking, 1.25 with the constraint.
The results from the ligand screener using the PDB overlay show much better results both
with and without the similar molecules removed, as compared to the other methods. Visual
inspection of the overlaid PDB ligands (figure 5.11) show that although most of them do
make the highlighted interaction, they extend towards the left, whereas the apolar map used
for the ligand screener highlights the more buried region to the right. It is unlikely that the
ligand screener will attempt to place the ligands in the correct orientation as a result of this.
This binding site yields very low scoring Fragment Hotspot Maps. The maps in figure
5.11 were contoured at an absolute score of 12, showing that this site does not contain a
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(a) Docking (b) Docking with constraint
(c) Docking with strong constraint (d) Ligand Screener
(e) Crystal ligand displayed with maps contoured at the 95th percentile, an
additional contour level of 17 for the apolar map is also displayed. The
sphere denotes the atom used as the hydrogen bond constraint in docking.
Crystallographic ligand is shown as cyan sticks
Fig. 5.9 ROC curves and binding site for AKT1
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hotspot. Fortuitously, a ligand deconstruction experiment was performed on this target by
Babaoglu and Shoichet[199]. Upon deconstruction of this ligand into fragments, none of
the fragments managed to recapitulate the binding position of the larger ligand. Previous
work [200] by Kozakov and co-workers found that fragments from a deconstructed ligand
would only maintain its binding position if it had sufficient overlap with a hotspot. Typically,
fragmentation would result in multiple fragments occupying a single hotspot, however the
work by Babaoglu and Schoichet found that the fragments were located in several new
binding positions. This indicates that a hotspot is not present.
Interestingly, while AMPC is normally rigid and undergoes little conformational change
upon binding of lead-like molecules, the small fragments do result in conformational change.
Maps calculated from the fragment bound structures (PDB: 2HDQ) show a strong hotspot
present (figure 5.12). This suggests that the dynamic motion of the protein generates
conformations which create a hotspot that larger ligands are unable to satisfy, but that a
fragment is capable of stabilising.
5.3.5 CP3A4
Cytochrome P450 3A4 (CP3A4) is a metabolic enzyme found in the human liver, and known
to bind a large variety of drug-like molecules[201]. As a result, it is not expected to be a
particularly good candidate for virtual screening. AUCs for docking are again fairly low,
but showing improvement over random. An AUC of 0.63 was achieved with or without the
constraint included (figures 5.13a and 5.13b).
The constraint was applied to the hydrogen of the serine 119’s hydroxyl group (figure
5.13d), meaning that the hydroxyl was acting as a hydrogen bond donor. SuperStar, and
by extension Fragment Hotspot Maps, treat hydroxyls as rotatable, therefore there are
overlapping regions of donor and acceptor propensity surround the serine. GOLD is also
capable of rotating hydroxyl groups, however the constraint was applied to the hydrogen
atom, and therefore not satisfied if the hydroxyl group was acting as an acceptor. The
crystal structure ligand forms a hydrogen bond between the NH of the carbamate and the
oxygen of the hydroxyl, however this results in the hydroxyl hydrogen pointing towards
hydrophobic residues. Addition of the constraint manages to improve enrichment at 1%
from approximately 4 to 7, suggesting that some actives do use the hydroxyl as a donor.
It is possible that having the ability to act as donor or acceptor within a hotspot at CP3A4
contributes to its promiscuity.
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(a) Docking (b) Docking with constraint (c) Ligand Screener
(d) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks.
Fig. 5.10 ROC curves and binding site for AMPC
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Fig. 5.11 AMPC with ligand overlay. Overlaid ligands are displayed as green lines, the crystallo-
graphic ligand is shown as cyan sticks. An additional contour of the apolar map is shown at the 60th
percentile, showing the minimal overlap between grid points used for the apolar ligand screener maps
and the experimental ligands.
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Fig. 5.12 AMPC with fragments. Small fragments with new binding mode are shown in cyan sticks.
The larger fragment, which maintains its binding mode from its parent ligand is shown in magenta.
Maps are calculated from the protein structure of the cyan fragments, apolar map is contoured at 17,
acceptor map is contoured at 14.
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The PDB-LS only just outperforms using the HS-LS, and removing PDB structures that
are similar to those found in the active set (nPDB-LS) essentially reduces the performance
down to random.
(a) Docking (b) Docking with constraint (c) Ligand Screener
(d) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks.
Fig. 5.13 ROC curves and binding site for CP3A4
5.3.6 CXCR4
C-X-C chemokine receptor type 4 (CXCR4) is an example where the ligand screener outper-
forms docking, however neither of the methods manage to achieve good early enrichment.
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CXCR4 has the fewest actives in the dataset, and it is again more appropriate to look at the
EF at 10%.
The polar atom selected for the docking constraint is one of the carboxylate oxygens of
aspartate 95, which can be seen interacting with one of the nitrogens of the symmetrical
isothiourea group. These are both protonated with a net positive resonance charge[202]. This
interaction is important for affinity, and methylation of this nitrogen results in a 100-fold
loss in potency[203]. Despite a suitable interaction being set as a constraint, it has minimal
impact on either the AUC or EF at 10%.
The HS-LS method managed to almost match both the AUC and EF at 10% of the
PDB-LS method (tables 5.6 and 5.8. All of the PDB ligands were found to be above the
similarity threshold to the active set, therefore it was not possible to calculate the nPDB-LS
results.
5.3.7 GCR
Glucocorticoid receptor (GCR) shows the greatest difference between docking and the ligand
screener. Docking performance is fairly poor with respect to AUC, with AUCs of 0.56
(no constraint, figure 5.14a) and 0.57 (with constraint, figure 5.14b. Docking does give
reasonable early enrichments (table 5.4), with 5.04 being improved to 8.52 upon addition of
the constraint shown in figure 5.14d.
In the DUD-e publication[195] all targets were tested with DOCK 3.6, and GCR was in
the bottom 4 of all 102 targets. It was described as a particularly difficult target to dock into
as it was a very hydrophobic and flexible pocket. In contrast to the performance of docking,
the ligand screener does very well. Where the ROC curves for the docking results (figure
5.14a) dip below the random line after initial enrichment, the ligand screener (figure 5.14c)
stays well above it, resulting in much higher AUC values.
The difference in performance between docking and the field-based ligand screener for
GCR suggests that the two methods may have orthogonal uses. It could be that the "fuzzy"
nature of the ligand screener fields, whether generated from Fragment Hotspot Maps or a
ligand overlay, are more suitable for flexible targets. Furthermore, the ability of Fragment
Hotspot Maps to precisely locate the hydrophobic hotspot within the binding site allows for
good performance with hydrophobic binding sites.
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(e) Docking (f) Docking with constraint (g) Ligand Screener
(h) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks
Fig. 5.13 ROC curves and binding site for CXCR4
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(a) Docking (b) Docking with constraint (c) Ligand Screener
(d) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks
Fig. 5.14 ROC curves and binding site for GCR
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5.3.8 HIVPR
Human immunodeficiency virus type 1 protease (HIVPR) has a good AUC and early enrich-
ment for both methods. In terms of AUC the ligand screener outperforms docking both with
and without constraints, however docking gives a superior early enrichment. Both AUC and
EF are improved for docking upon addition of the constraint. The aspartates of this aspartyl
protease were not selected as the highest scoring interaction by the Fragment Hotspot Maps,
as charged probes have currently not been implemented. Instead, the backbone carbonyl
oxygen of Gly-34 was set as the protein hydrogen bond constraint, still resulting in an
increase in early enrichment from 12.50 to 15.30.
5.3.9 HIVRT
Human immunodeficiency virus type 1 reverse transcriptase (HIVRT) shows reasonable
docking performance for both AUC and EF, but performs poorly with the the field-based
ligand screener. Addition of the docking constraint improves both AUC and EF; the atom
selected for the constraint is the only polar atom to interact with the crystallographic ligand
(figure 5.16d). The poor performance of the ligand screener is surprising as the maps seem to
match the crystallographic ligand well. Conformational change of the binding site is unlikely
to be the cause of the poor performance, as this would have affected the docking results
as well. Comparing the HS-LS results to the nPDB-LS results show that the experimental
overlay of ligands performs equally badly.
5.3.10 KIF11
In this dataset, the binding site on Kinesin-like protein 11 (KIF11) is allosteric. From
figure 5.17c you can see that the binding site is shown to be hydrohphobic and lacking
in polar interactions. This is in line with an analysis of ligands in ChEMBL[204], which
found allosteric inhibitors to be more lipophilic and rigid. As a result, no polar interactions
were found above the score threshold required to define a protein hydrogen bond constraint.
Despite the lack of polar features, KIF11 performed very well with both docking and the
ligand screener. Comparing the different ligand screener approaches, KIF11 gave the second
highest AUC values for the HS-LS method, beaten only by the other hydrophobic binding
site of GCR. The AUC and EF values for the PDB-LS and nPDB-LS methods are the best
for all targets across all methods.
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(a) Docking (b) Docking with constraint (c) Ligand Screener
(d) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks
Fig. 5.15 ROC curves and binding site for HIVPR
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(a) Docking (b) Docking with constraint (c) Ligand Screener
(d) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks
Fig. 5.16 ROC curves and binding site for HIVRT
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(a) Docking (b) Ligand Screener
(c) Crystal ligand displayed with maps contoured at the 95th percentile. The sphere denotes the atom
used as the hydrogen bond constraint in docking. Crystallographic ligand is shown as cyan sticks
Fig. 5.17 ROC curves and binding site for KIF11
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5.4 Conclusion
The work carried out in this chapter aimed to use the knowledge gained from a Fragment
Hotspot Maps calculation, and apply it to existing virtual screening tools. Using the Hotspot
API functions discussed in chapter 4, two approaches were taken. Firstly, the highest scoring
polar interaction in the binding site was set as a "protein hydrogen bond constraint", meaning
that any pose that fails to make that interaction will have a penalty applied to it.
The second approach was to use the maps more directly, making use of the field-based
ligand screener. This tool is typically part of a larger ligand-based workflow, however the final
step involves sampling ligands in a field-based pharmacophore model. Fragment Hotspot
Maps were adapted such that they can be used by the ligand screener program to screen
molecules against the maps directly.
Docking constraints selected by choosing the highest scoring polar interaction in the
binding site led to improved performance in all but two cases, where no change was observed.
Improvements were small in terms of AUC but larger for EF. Increasing the penalty of the
constraint from the default of 10 to 100 saw a much greater improvement in performance.
This initial work has shown that information from Fragment Hotspot Maps can be used to
improve the performance of docking, but further work is required to find the optimal penalty
to use. While this work used a single polar constraint, it is also possible to select multiple
constraints. Although not tested here, functionality has been added to the Hotspots API
to convert the apolar maps to to hydrophobic fitting points. By default, GOLD generates
hydrophobic fitting points by calculating the Van der Waals interaction between the protein
and a carbon atom, and the Fragment Hotspot Maps method provides an alternative method
for highlighting favourably hydrophobic areas. The default fitting points often fill much of
the cavity, therefore those derived from Fragment Hotspot Maps offer an opportunity to have
more targeted hydrophobic interactions.
Using the field-based ligand screener with modified Fragment Hotspot maps provides an
alternative structure-based virtual screening workflow to docking. The performance of this
approach was compared to using the field-based ligand screener with an input of overlaid
ligands from multiple ligand-bound protein crystal structures. This represents the best case
scenario, and shows the performance of the field-based ligand screener itself. Additionally,
the ligand screener was provided a subset of these overlaid ligands with molecules similar to
actives within the test set removed. This represents the field-based ligand screener’s ability
to find novel chemistry.
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Comparing AUCs of calculations from docking and the field-based ligand screener shows
that for most targets they give a similar performance, with the clear exception of GCR. The
flexible and hydrophobic nature of GCR has made it a difficult target for virtual screening,
reflected in the poor docking performance shown in this chapter. The good performance
of the field-based ligand screener can potentially be attributed to two things. Firstly, the
"softer" nature of field-based ligand screening can be more forgiving of clashes when the
shape of the crystal structure does not match the bound conformation of the protein. This
could make the field-based ligand screener a more suitable structure-based virtual screening
tool for highly flexible sites and homology models. Secondly, the hydrophobic maps have
be shown previously[1] to perform well at specifically locating the fragment binding site,
allowing for more precise placement of hydrophobic groups in lead-like molecules.
Comparing the AUCs of the field-based ligand screener results from the three different
input types shows that in cases where a reasonably strong hotspot is found, the HS-LS
calculations can offer similar performance to the best case scenario of the PDB-LS. For all
targets, percentiles of the map scores were used rather than the absolute values (95th and 60th
rather than 17 and 14). This produced ligand screener maps with consistent volumes for each
binding site, however AMPC did not have a predicted hotspot, and performed very poorly.
When ligands similar to those in the test set are removed, nPDB-LS, AUCs were greater
than those from HS-LS in only two out six applicable cases (two the same, two lower). This
suggests that, in terms of AUC, virtual screening using the HS-LS method can offer similar
performance at identifying novel chemistry to using experimentally overlaid ligands from
protein-ligand crystal structures. The HS-LS method generally showed lower EFs for most
targets when compared to both docking and PDB-LS. The low early enrichment shows a
need for optimisation of the scores of the ligand screener grids generated from the Fragment
Hotspot Maps.
The two methods discussed in this chapter provide orthogonal structure-based virtual
screening approaches. While this work requires optimisation, it suggests that Fragment
Hotspot Maps can be used in virtual screening both directly with the field-based ligand
screener, and indirectly with constraints in docking. When combined with the Hotspots
API, discussed in the previous chapter, these improvements can be achieved with simple
Python scripts that require minimal knowledge of Python. Importantly, these approaches
have demonstrated that they can improve virtual screening from the structure alone, making
use of tools that typically require large amounts of experimental knowledge of the binding
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site. The Hotspot API provides a framework for systematic detection of ligandable pockets
in the PDB, and subsequently running a virtual screen against these pockets.
Chapter 6
Current and Future Uses of Fragment
Hotspot Maps
6.1 Introduction
This chapter will explore recent work and examples of Fragment Hotspot Maps being used to
learn about a target at varying stages of the drug discovery process, still a matter of ongoing
research for me and collaborators. Each of these research areas will be discussed below. I
will indicate what has been achieved so far and what plans there are for the future.
6.2 Pocket Tractability Assessment
Fragment hotspot maps can be used as a direct score of ligandability. As fragment hit rate
has been shown to correlate with ligandability [25], a computational method that can predict
fragment binding may also be able to predict ligandability. This has been demonstrated
recently [110] by using hotspots predicted by FTMap, combined with the volume of the
pocket and the density of hotspots. As the scores from my Fragment Hotspot Maps method are
comparable across targets, due to their probabilistic origin of sampling SuperStar propensities,
the cut-offs of 14 and 17 can be used to assess the ligandability of a target. This is ligandability
in the true sense, as it is possible that a pocket is large enough to accommodate a hotspot, but
not a drug-like molecule.
Since the start of August 2017 I have been working at the European Bioinformatics
Institute (EBI) looking large scale tractability assessment as part of the open target platform.
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As part of this, I have been investigating how Fragment Hotspot Maps can be used to aid
large scale tractability assessment.
Structure-based tractability-prediction methods are sensitive to the initial pocket defini-
tion. Slight changes in the conformation of the binding site can cause separate pockets to
be considered as one, yielding extremely large pockets. This causes problems for methods
that have been trained on cavity properties, as the global measures used change drastically.
Volkamer and colleagues attempt to deal with this problem with DoGSiteScorer, by using the
difference-of-Gaussians method to detect subpockets [37]. These subpockets are ultimately
joined together to create pockets, however properties and druggability scores are created for
both the subpockets and pockets. Figure 6.1 shows the highest scoring pocket and sub pocket
for Glucocorticoid receptor (GCR). In this example, the subpocket still extends beyond the
ligand binding site. As the pocket is considered as a whole, fine details, such as the location
of the hotspot, are lost.
Fragment Hotspot Maps provide finer detail than pocket-based methods, as well as a
continuum of scores from the hotspot to the full pocket. It is possible to define a “fragment-
sized”, “lead-sized” or “drug-sized” volume, and select the highest scoring regions occupied
by this volume. This gives a better reflection of reality, as ligands can often occupy only part
of the pocket, exemplified in figure 6.1. The top left image shows the Fragment Hotspot Map
output at a low score contour, highlighting all of the pockets that have been sampled. The top
middle image shows the top 300Å
3
, and although the majority of the propensity surrounds
the ligand, in this early implementation some propensity can be found in other pockets. This
will be prevented in future by only allowing a single volume to contribute to the total volume.
The image on the top right shows the highest scoring 150 Å
3
, which is now smaller than the
displayed ligand.
Future work will look at the distribution of scores from maps contoured at given volume,
exemplified in figure 6.2 (histograms created using a Hotspot API function written by Pete
Curran). The distributions will be calculated for sets of tractable and intractable targets,
training a support vector machine (SVM) model to classify pockets. This is a similar approach
to the one used in VolSite by Desaphy and colleagues [205], however VolSite uses more
simple interaction grids and suffers from the same pocket prediction problem identified
above. This work should provide a better method for defining a binding site to be used with
existing structure-based tractability methods, and offers a potential method for using the
maps themselves.
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Fig. 6.1 Fragment Hotspot Maps contoured by volume, compared to pocket detection by
DoGSiteScorer. (Top) GCR with maps contoured to show all pockets(left) 300 Å
3
(middle) and
150 Å
3
. (Middle) A closer look at the binding site with maps contoured at 150 Å
3
, ligand shown
in magenta sticks. (Bottom) The pocket (orange) and subpocket (purple) for the same structure, as
predicted by DoGSiteScorer.
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Fig. 6.2 Map score distribution at volume cut-off. Histograms of the top scoring 150 Å3 are shown
from two pockets, previously identified as ligandable (GCR, PDB 3BQD) and unligandable (BAZ2B,
PDB 3Q2F).
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6.3 Decorating Proteomes with Hotspots
Due to the speed of the calculation, it has been possible to calculate Fragment Hotspot Maps
for over 9000 ligand-bound structures in the PDB. Although analysis of these data cannot be
completed within this PhD project, it will be taken over by another group member. The aim
is to refine the cut-off scores for fragments and lead-like molecules defined above by looking
at the distribution of scores for both molecule types, and begin to look in to how well the
highest scoring interactions match up with chemistry found in the PDB.
As this initial work shows, the ability to automate and the speed of this method allows
for analysis of large numbers of structures. Recent work by Somody and colleagues [206]
has shown that structural coverage of the human proteome at 30% sequence identity and
above is approaching 70%. This corresponds to estimates from the Blundell group that rea-
sonable models are available for approximately 70% of both the human and Mycobacterium
Tuberculosis proteomes [207]. Although work is required to assess how sensitive Fragment
Hotspot Maps are to homologous structures or homology models, it should be possible to
decorate a large portion of the human proteome with hotspots. As many of the methods
described in chapter 4 require a negligible amount of computation time as compared to the
generation of the maps, it will also be possible to run these for each of targets. This includes
the generation of pharmacophores, scoring of any ligands and assignment of scores to protein
atoms. The work from this project has led to a follow up PhD project titled “Global Analysis
of Pharmacophoric Space”. Pharmacophores derived from the hotspot interactions will be
used to design and synthesise a chemical library that could deliver hits to any given folded
protein target.
Decoration of a proteome also offers the potential to bridge structural and sequence data.
As scores can be assigned from the maps to protein atoms, it is possible to annotate the
protein sequence with hotspot scores. Residues at functionally important binding sites tend to
have greater evolutionary conservation [208], and previous methods have used conservation
scores in combination with 3D pocket detection methods to predict ligand binding sites [209].
As an alternative approach, a database of "hotspot motifs" could be created from high scoring
regions of annotated sequences. These motifs may have large gaps as distant parts of the
sequence are brought close together by the tertiary structure, however these regions are more
likely to remain conserved. A query sequence can be compared to the database of hotspot
motifs using software such as InterProScan [210]. This method provides two opportunities.
Firstly, it can identify targets that may contain a hotspot from their sequence alone. Secondly,
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as the hotspot motif will have a link to its original structure, this approach could identify
targets with a high homology at the site of the pocket, even when overall sequence identity
is low. This work will be explored further in my large scale tractability project at the EBI,
where a tractability assessment for targets without a structure is required.
6.4 Decorating MD Trajectories with Hotspots
In addition to looking at larger numbers of crystal structures, this can also be applied to
frames extracted from MD simulations. As a proof of concept, 6000 frames from an MD
simulation were processed within 48 hours on a Linux workstation. It is possible to visualise
the maps for each frame to see how they are affected by the dynamics of the protein. Another
way to view the data across the MD trajectory is through the calculation of summary maps.
Average maps, shown in figure 6.3, give the average score for each grid point across all
the frames. This has the effect of smoothing out the noise in data, removing any artefacts
caused by flexible regions being fixed or restrained in the crystal structure. The second is
the "maximum" summary map. This captures the highest score achieved by each grid point
across the frames. The purpose for this map is to capture hotspots when they appear during
the simulation. This work will be continued further by collaborators at UCB.
6.5 Prioritising Fragment Hits
Another use is to prioritise crystallographic fragment screening hits. It is clear that fragments
can bind to a protein, without being bound to a hotspot (Alicia Higueruelo, Sherine Thomas
and Tom L Blundell, Unpublished). In this situation, the fragment may no longer bind in
the same pose or at all upon elaboration. The recently developed PanDDA approach [90]
is able to identify a far greater number of fragment binding sites. This method does an
excellent job of extracting as much data from the electron density as possible. This gives a
good representation of the crystallographic environment, however not all of these sites would
be suitable starting points for a drug discovery project. An example is given in figure 6.4,
where several fragment-bound structures have been overlaid with the results from a Fragment
Hotspot Maps calculation.
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Fig. 6.3 Bcl-xl with the average hydrophobic map from 6000 MD frames. Apo Bcl-xl displayed as a
green cartoon with a magenta ligand for reference. The average hydrophobic map is displayed as a
yellow surface
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Fig. 6.4 ATAD2 overlaid with fragments identified by PanDDA. Fragment Hotspot Maps are shown
contoured at 17. Several fragment binding sites are identified, but many are highly exposed, and not
predicted to bind to hotspots.
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6.6 Hit-to-lead Development
Fragment Hotspot Maps will be useful to both medicinal chemists and molecular modellers.
For the medicinal chemist, the maps will be a visual guide to the most important interactions
within the pocket, as demonstrated retrospectively with the examples of protein kinase B
and pantothenate synthetase. Once a structure containing a hit is available, it will be easy
to determine whether any of the existing groups are suboptimal. The maps will suggest the
direction in which the hit should be grown and which types of interaction are required.
An example of Fragment Hotspot Maps guiding fragment growth has been given in figure
6.5. A PyMOL session containing experimental data and the Fragment Hotspot Maps was
kindly provided by Sherine Thomas, a fellow member of the Blundell group. I would also
like to acknowledge the contributions of Andrew Whitehouse, Alexander Fanourakis, Dr.
Anthony Coyne and Prof. Chris Abell at the department of Chemistry to this work. As the
compounds are currently unpublished, they have only been represented as wire meshes.
Dissociation constants (Kds) were calculated for the original fragment hit (compound 1
Kd = 104 µM), first elaboration (compound 2 Kd = 32 µM) and second elaboration (compound
3 Kd = 9 µM). The pocket has four polar interactions with scores greater than 17, two of which
are made by the fragment. Compound 2 extends further into the hydrophobic propensity, but
does not make any additional polar interactions. Compound 3 extends fully into the identified
hydrophobic region, but again does not make any direct polar interactions with the protein.
Instead, it appears as though the region of donor propensity, shown at the bottom of each
image in figure 6.5, is in fact a water binding site, which bridges an interaction with the ligand.
The fact that high scoring interactions sometimes correspond to stable water-binding sites is
undesirable behaviour, and will be discussed further in chapter 7. The final polar interaction
is beyond the reach of compound 2, and presents an opportunity for further growth. As
evidence supporting the hypothesis that this is indeed an important interaction, compound 1
has a second binding mode in the crystal structure where it is found to make this interaction.
It could be argued that you simply need to look at the protein structure to identify where
polar interactions are, and growing fragments is a case of picking up these interactions as
they are grown into space, however this ignores the varying behaviour of water in the binding
site. This example demonstrates two benefits of using Fragment Hotspot Maps. Firstly, it is
capable of prioritising the numerous available interactions. Often, as in this case, the highest
scoring interactions will be made by the fragment already, however those remaining high
scoring interactions offer a chance for improved affinity. Secondly, Fragment Hotspot Maps
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are capable of precisely locating hydrophobic regions which correspond to useful warm spots.
In addition to compound 2 in figure 6.5c, this was exemplified retrospectively in chapter
3 looking at the growth of fragments targeting pantothenate synthetase in figure 3.8. In
this example, two high scoring hydrophobic regions were identified, and initial work led to
growing the fragment into the lower scoring of the two. Later, it was found that growing into
the region identified as the highest scoring led to more potent compounds.
6.7 Conclusion
The initial development of the Fragment Hotspot Maps method was completed mid way
through this PhD project. As a result, this has given me time to explore how it can be used
to help structure-based drug design. This chapter has given a brief overview of ways in
which the method is used currently, and how collaborators and I intend to use it in the future.
Much of the work moving forward has benefited from the development of the Hotspots API,
described in chapter 4. The Hotspots API can be regarded as a tool kit, with functionality
ranging from virtual screening to fundamental methods, such as scoring the protein. Having
produced this tool kit, other scientists will be able to focus on being creative and working out
how they can use the knowledge that Fragment Hotspot Maps provide.
6.7 Conclusion 139
(a) Compound 1: Kd = 104 µM (b) Compound 2: Kd = 32 µM
(c) Compound 3: Kd = 9 µM
Fig. 6.5 Fragment growing guided by Fragment Hotspot Maps. All maps are contoured at 14, and
ligands are shown as a wire mesh. The colour of the mesh represents the atom type, cyan for carbon,
blue for nitrogen and red for oxygen.

Chapter 7
Discussion and Conclusions
7.1 Summary
Fragment-based drug design is now a mainstream approach in drug discovery, but few
computational methods have been designed specifically to support it. Existing computational
hotspot detection methods are either capable of locating fragment binding sites from a global
search of a protein [123, 122], or highlighting important interactions within a predefined
binding site [143, 130]. Computational methods were able to replicate multiple solvent
crystal structure experiments only once solvation was accounted for, explicitly or implicitly
[160].
Separate publications looking at unhappy waters [130], fragment-binding sites [132] and
hotspots [110] each identified the required protein environment as having hydrophobic enclo-
sure with a mixture of polar and hydrophobic interactions. This prompted the development
of the Fragment Hotspot Maps method, which aimed to locate these protein environments.
Hotspots were defined as follows:
Hotspots are the minimum binding site that will bind a fragment, maintaining the
fragment binding position once it has been elaborated
The calculation of Fragment Hotspot Maps is a CSD-derived computational approach,
with a knowledge-based origin that makes it much faster than existing approaches. Calcu-
lations can be completed within minutes rather than hours [110]. Fragment Hotspot Maps
provide a continuum of scores, which describe the relative likelihood of discovering the given
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interaction type at each grid point. Increasing the value at which the maps are contoured
locates the most attractive regions and interactions within a pocket.
Given the above hotspot definition, a previously published [132] dataset of fragment-lead
pairs was an ideal dataset for testing Fragment Hotspot Maps. The ligand bound protein
crystal structures were aligned to apo protein crystal structures, which were used for the
calculation of Fragment Hotspot Maps. The maps were able to specifically identify fragment
binding sites and their interactions over the larger ligand-binding site.
A web application was developed to provide a simple user interface for both submitting
calculations and viewing results. Minimal user input is required to download and prepare
a protein from the PBD. NGL viewer [173] is used to display the protein and maps, which
can be contoured interactively using a slider. Changing the contouring value modifies the
description of how likely the site is going to be a hotspot.
In addition to the web server, the Hotspots API was developed to provide easy and
scriptable access to Fragment Hotspot Map calculations. The Hotspots API provides methods
for using the information provided by the maps, ranging from simple tasks such as scoring
ligand atoms, through to higher-level functions used for virtual screening. The purpose of
this work was to create a tool kit to allow other researchers answer their own questions more
easily.
To highlight how the Hotspots API can be used to help in structure-based drug design, two
of the three virtual screening workflows were applied to the DUD-e test set [195]. Docking
was performed both with and without a hotspot-derived constraint, and performance either
improved or remained the same. Increasing the weighting of the constraint led to further
improvement in performance. The second approach was to use a field-based-ligand screener
with modified Fragment Hotspot Maps as input. This was compared to the best case scenario
of running the field-based ligand screener with a set of overlaid ligands from multiple protein
crystal structures. While often unable to match the early enrichment of the ideal scenario,
it showed comparable or better performance at locating novel chemistry. Interestingly, the
highly hydrophobic and flexible target GCR performed poorly with docking both in this and
previous studies [195] but performed very well using the field-based ligand screener with
Fragment Hotspot Map input. This may suggest that this work flow is more suitable for
targets of this type, or where docking has previously performed poorly.
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Literature discussing the nature of hotspots [132, 110, 130] was used early on in this project
to guide the development of the Fragment Hotspot Maps method, and its success adds further
confidence to this view of hotspots. While previous methods [143, 122] stated that solvent is
required to remove false positives, this work agrees with that of Brenke and colleagues [123],
who showed that a "cavity" term can be used to give a similar effect.
Most current hotspot detections methods use MD [133], however FTMap [123] uses a
static protein structure and is the closest to the Fragment Hotspot Maps method. It scans
the surface of a static protein structure with molecular probes, and is capable of locating
fragment-binding sites from a global search of the protein. To my knowledge, FTMap is
the only other software reported to be able to do this. The Fragment Hotspot Map method
has also demonstrated its ability to locate fragment-binding sites, however it is able to do
so in approximately 5-30 minutes, rather than 4-24 hours required by FTMap [110]. This
has opened up the possibility of performing wide scale analyses of the human proteome, as
discussed in the previous chapter.
Fragment Hotspot Maps highlight the specific interactions within the hotspot, making it
possible to generate a pharmacophore model for each of these predicted hotspots. Similar
work by Yu and co-workers [211] uses the SILCS MD-based method to identify important
interactions within a pre-defined binding site, which they used to generate pharmacophores.
The Hotspots API provides a set of tools to incorporate information about the highest
scoring interactions into existing structure-based workflows. While docking requires an
expert user to yield the best results, the docking work flow used in chapter 5 could be
used to set multiple suggestions for docking constraints and the user select a sensible
combination. Earlier this year, around the same time the docking work described in chapter
5 was performed, Arcon and colleagues [142] used the results of mixed solvent molecular
dynamics to improve docking. In this work the authors modified the scoring function for
AutoDock [212] and assessed their ability to correctly predict the crystallographic poses for
two targets. The mixed MD method is used to identify favourable probe binding positions,
which are then used to bias the scoring function, however the workflow started from a ligand
bound structure (with the ligand removed) and with the binding site defined. Although
binding sites are typically known before docking calculations are performed, and is therefore
sensible for this use, it demonstrates that this method is not capable of detecting hotspots
from a global search.
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Fragment Hotspot Map calculations are not only faster than existing hotspot detection
methods, but also provide the best features of each: identification of fragment binding sites
from a global search of the protein plus highlighting key interactions within the binding site.
In order to allow other scientists to get the most out of this program, a programmatic tool kit
has be produced to allow them to incorporate Fragment Hotspot Map calculations into their
existing work flows.
7.3 Remaining challenges
While the work described in this thesis aims to improve upon existing hotspot detection
methods, the provision of interaction information leads to extra challenges. As described
above, this work found it was possible to use a cavity/buriedness term in place of solvation.
While this is capable of locating unfavourable water regions, the current implementation
finds that known structural waters coincide with high scoring regions of the map, suggesting
they should be displaced by a fragment. However, Ichihara and colleagues [132] found both
types of hydration site could be displaced upon fragment binding (figure 7.1).
• Overall positive excess free energy compared to bulk water (i.e. unhappy water),
with positive excess enthalpy (∆H) and entropy (−T∆S) contribution. These water
molecules are unable to satisfy their hydrogen bonding capabilities as well as in bulk
solvent. Any hydrogen bonds made to the protein or neighbouring water molecules
restrict the motion of the molecule. Displacement of this water is relatively easy.
• Overall negative excess free energy compared to bulk water (i.e. happy water), with
large negative excess enthalpy (∆H) and large entropy (−T∆S) contribution. The water
molecule makes a very strong interaction with the protein, and its hydrogen bonding
capabilities are well satisfied. Due to enthalpy-entropy compensation [180], the water
molecule has a large positive excess entropy (−T∆S) and is held tightly in place.
Displacement of this water requires the ligand to precisely replace the interactions of
the water molecule.
The fact that waters in energetically favourable positions (happy waters) can be displaced
to improve ligand binding may seem counter-intuitive. To rationalise this, the energy of
the protein ligand binding event must be considered as a whole. These waters are in a
favourable position compared to bulk water due to large but opposing enthalpic and entropic
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Fig. 7.1 The excess enthalpy (∆H) and entropy (−T∆S) of the hydration sites displaced by fragments
and lead compound. Hydration sites displaced by fragments are shown in red, lead compounds in
blue. The two circled regions represent types of hydration sites exclusively displaced by fragments.
Image taken from the original publication [132]
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terms. A ligand can benefit from this by replacing the interaction of the water, negating the
enthalpic penalty whilst benefiting entropically through the release of the highly constrained
water. To do so, ligands must provide precisely matched hydrogen bonds to replace those
of the water. On average, fragments make two well-made hydrogen bonds [213], and their
simplicity allows them to make the highly geometrically constrained interactions. Replacing
the interactions with a ligand negates the lost excess enthalpy upon displacing the water,
but benefits entropically from the release of the highly constrained water. Ichihara et al
[132] state that if a fragment is able to displace such a water, it should be prioritised, as it is
easier to grow the fragment into the unhappy water sites, which can often by displaced by
hydrophobic groups.
These sites are currently predicted as highly scoring by the Fragment Hotspot Map
calculations, which is good for prioritising crystallographic fragment hits, but bad when
highlighting interactions that should be targeted by prospective ligands. While some frag-
ments can make these interactions by chance, designing chemistry to match them is far more
difficult. These sites are often highly scoring due to the fact that multiple protein hydrogen
bonds are directed towards the same region. SuperStar only accounts for the position of
the probe atom, and does not account for the direction or quality of a hydrogen bond. As
a result, despite using relatively large probes, polar interactions that would be difficult to
make in reality are sampled easily and score highly. A potential approach to avoid finding
geometrically constrained polar interactions is to post-process the molecular probe poses to
eliminate those with poor quality hydrogen bonds. This should have only a small impact on
performance, whilst removing the harder-to-reach interactions.
7.4 Concluding Remarks
The field of computational hotspot detection seems to be moving towards MD, which is
unsurprising given the recent improvements in computational performance [214], and the
importance of protein flexibility in SBDD. Kozakov and colleagues have shown previously
that FTMap can correctly identify hotspots even when large conformational changes take
place [144]. This does not extend to cryptic sites [215] - the pocket needs to exist - however
their method is robust enough to deal with changes in pocket shape. This is also true for
Fragment Hotspot Maps; apo structures were used in chapter 3 to identify fragment-binding
sites. While hotspots are not sensitive to these changes, the more precise positions of
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individual interactions will move with the groups that cause them. This a problem in SBDD
as a whole, and existing methods have been developed to deal with this: pharmacophore
models allow a search tolerance, docking can use an ensemble of structures or allow side
chain flexibility. For now, I feel MD-based hotspot detection methods have not demonstrated
the ability to selectively highlight fragment binding sites as effectively as either Fragment
Hotspot Maps or FTMap.
The Fragment Hotspot Map method has been developed with FBDD in mind, but is useful
for SBDD in general. This can be viewed as a computational equivalent to "fragment-assisted"
drug discovery, where knowledge from fragments can be incorporated into molecules discov-
ered by other means [216]. Fragments bound at hotspots are highlighting highly important
interactions, which should be optimally matched in larger molecules. Knowledge of these
interactions a priori can lead to more useful computational experiments ahead of a focussed
screen, or to even predict the binding mode of fragments that lack a crystal structure.
The recently published improvement to X-ray crystallography, PanDDA [90], has shown
that fragment binding alone is no longer enough to suggest the presence of a hotspot.
While PanDDA is very good at using electron density data to show what is present in the
environment of the crystal, it presents a challenge: how do you choose which fragments
to progress? The computational assessment of fragment binding sites continues to provide
important information at multiple stages of the drug discovery process. Fragment Hotspot
Maps, in combination with the Hotspots API, can help scientists select tractable pockets,
select compounds to screen, prioritise experimental hits and guide hit-to-lead development.
With the ever-increasing structural coverage of the human proteome, large-scale structure-
based assessment of protein targets is on the horizon. I believe the work described in this
thesis can aid not only in this work, but also in the discovery of drugs for the novel targets
found.
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